<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002178" GROUP_ID="AIRWAYS" ID="893700021415501013" MERGED_FROM="" MODIFIED="2008-07-23 16:47:49 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Corticosteroids and asthma admission&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:38:03 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="SYS-AST" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-07-23 16:47:49 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Early emergency department treatment of acute asthma with systemic corticosteroids</TITLE>
<CONTACT MODIFIED="2008-07-23 16:47:49 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="FB72D3DD82E26AA20100F9CCFABFA64F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Rowe</LAST_NAME><SUFFIX>MD, MSc, CCFP (EM), FCCP (BR)</SUFFIX><POSITION>Professor and Research Director</POSITION><EMAIL_1>brian.rowe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Room 1G1.43 Walter C. Mackenzie Health Sciences Centre</ADDRESS_1><ADDRESS_2>8440  112th Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 6707</PHONE_1><PHONE_2>+1 780 407 6761</PHONE_2><FAX_1>+1 780 407 3982</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-23 16:47:49 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="FB72D3DD82E26AA20100F9CCFABFA64F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Rowe</LAST_NAME><SUFFIX>MD, MSc, CCFP (EM), FCCP (BR)</SUFFIX><POSITION>Professor and Research Director</POSITION><EMAIL_1>brian.rowe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Room 1G1.43 Walter C. Mackenzie Health Sciences Centre</ADDRESS_1><ADDRESS_2>8440  112th Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 6707</PHONE_1><PHONE_2>+1 780 407 6761</PHONE_2><FAX_1>+1 780 407 3982</FAX_1></ADDRESS></PERSON><PERSON ID="5452" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Carol</FIRST_NAME><LAST_NAME>Spooner</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>cspooner@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of Emergency Medicine</DEPARTMENT><ORGANISATION>1G1.52 Walter Mackenzie Health Centre</ORGANISATION><ADDRESS_1>8440 - 112 ST</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407-7576</PHONE_1><FAX_1>+1 780 407-3314</FAX_1></ADDRESS></PERSON><PERSON ID="5253" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Francine</FIRST_NAME><LAST_NAME>Ducharme</LAST_NAME><EMAIL_1>francine.ducharme@mcgill.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>McGill University Health Centre</ORGANISATION><ADDRESS_1>Montreal Children's Hospital</ADDRESS_1><ADDRESS_2>2300 Tupper Street, Room C-538E</ADDRESS_2><CITY>Montreal</CITY><ZIP>H3H 1P3</ZIP><REGION>Quebec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 412 4400 ext: 22649</PHONE_1><FAX_1>+1 514 412 4393</FAX_1></ADDRESS></PERSON><PERSON ID="5211" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Jennifer</FIRST_NAME><LAST_NAME>Bretzlaff</LAST_NAME><POSITION>Research Assistant</POSITION><ADDRESS><DEPARTMENT>St Joseph's Site</DEPARTMENT><ORGANISATION>Sudbury Regional Hospital</ORGANISATION><ADDRESS_1>700 Paris Street</ADDRESS_1><CITY>Sudbury</CITY><ZIP>P3E 3B5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="5206" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gary</FIRST_NAME><LAST_NAME>Bota</LAST_NAME><ADDRESS><DEPARTMENT>St Joseph's Site</DEPARTMENT><ORGANISATION>Sudbury Regional Hospital</ORGANISATION><ADDRESS_1>700 Paris Street</ADDRESS_1><CITY>Sudbury</CITY><ZIP>P3E 3B5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-23 16:47:49 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 30/09/02&lt;/p&gt;&lt;p&gt;New studies sought but none found: 24/09/02&lt;/p&gt;&lt;p&gt;Reformatted: 15/02/00&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="24" MONTH="9" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="9" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2000"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2001"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;This is the first printed version of the review on the Cochrane Library.&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="2" MONTH="11" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Emergency Medicine, University of Alberta, Faculty of Medicine and Dentistry, Edmonton, AB</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Ministry of Health (Ontario); Emergency Health Services RAC #11469N</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-23 15:38:03 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-07-23 14:59:19 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-23 14:59:19 +0100" MODIFIED_BY="Toby J Lasserson">Early emergency department treatment of acute asthma with systemic corticosteroids</TITLE>
<SUMMARY_BODY>
<P>In an asthma attack, the airways (passages to the lungs) narrow from muscle spasms and swelling (inflammation). Bronchodilators (reliever inhalers to open up the lungs and airways) can be used for the spasms, and corticosteroids for the swelling. Corticosteroids can be inhaled, or taken by mouth (orally) or through a drip into the veins (intravenously). The review of trials found that systemic (oral or intravenous) corticosteroids reduce the need for people with asthma attacks to stay in hospital, with few adverse effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-23 14:59:07 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>The airway edema and secretions associated with acute asthma are most effectively treated with anti-inflammatories such as corticosteroids delivered by inhaled, oral, intravenous or intra-muscular routes. There is an unresolved debate about the use of systemic corticosteroids in the early treatment of acute asthma for emergency department patients. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the benefit of treating patients with acute asthma with systemic corticosteroids within an hour of presenting to the emergency department (ED).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomised controlled trials were identified from the Cochrane Airways Group Asthma Register. Primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies and known reviews were searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-07-23 14:59:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Only randomised controlled trials (RCTs) or quasi-randomised trials were eligible for inclusion. Studies were included if patients presenting to the ED with acute asthma were treated with IV/IM or oral corticosteroids (CS) versus placebo within 1 hour of arrival and either admission rate or pulmonary function results were reported.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial selection, data extraction and quality assessment were carried out independently by two reviewers, and confirmed with corresponding authors. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twelve studies involving 863 patients (435 corticosteroids; 428 placebo) were included. Early use of CS for acute asthma in the ED significantly reduced admission rates (N = 11; pooled OR: 0.40, 95% CI: 0.21 to 0.78). This would correspond with a number needed to treat of 8 (95% CI: 5 to 21). This benefit was more pronounced for those not receiving systemic CS prior to ED presentation (N = 7; OR: 0.37, 95% CI: 0.19 to 0.70) and those with more severe asthma (N = 7; OR: 0.35, 95% CI: 0.21 to 0.59). Oral CS therapy in children was particularly effective (N = 3; OR: 0.24, 95% CI: 0.11 to 0.53); no trials in adults used the oral route. Side effects were not significantly different between corticosteroid treatments and placebo. </P>
<P>An update search conducted in September 2002 did not yield any further trials. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Use of corticosteroids within 1 hour of presentation to an ED significantly reduces the need for hospital admission in patients with acute asthma. Benefits appear greatest in patients with more severe asthma, and those not currently receiving steroids. Children appear to respond well to oral steroids. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-23 15:38:03 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND MODIFIED="2008-07-23 15:02:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Acute asthma is a common presenting complaint to emergency departments (ED). In the United States alone, acute asthma accounts for almost 2 million ED visits per year (<LINK REF="REF-Mannino-1998" TYPE="REFERENCE">Mannino 1998</LINK>). Approximately 10-20% of these patients will require admission to the hospital, and, of those discharged from the ED after apparently successful treatment, approximately 10-20% will relapse within the subsequent two weeks (<LINK REF="REF-Camargo-1998a" TYPE="REFERENCE">Camargo 1998a</LINK>; <LINK REF="REF-Camargo-1998b" TYPE="REFERENCE">Camargo 1998b</LINK>). These results depend closely on the treatments prescribed in the ED and at discharge (<LINK REF="REF-Rowe-1997" TYPE="REFERENCE">Rowe 1997</LINK>; <LINK REF="REF-Rowe-1999" TYPE="REFERENCE">Rowe 1999</LINK>). Many asthmatics experience a poor quality of life for weeks following acute asthma during which they are particularly prone to repeat exacerbations (<LINK REF="REF-Fitzgerald-1990" TYPE="REFERENCE">Fitzgerald 1990</LINK>; <LINK REF="REF-Camargo-1998b" TYPE="REFERENCE">Camargo 1998b</LINK>). </P>
<P>Emergency treatment is based on the pathophysiology of acute asthma. Bronchospasm can generally be relieved with bronchodilators. The first treatment agents include beta 2-agonists which specifically target b-adrenergic receptors (<LINK REF="REF-Cates-2006" TYPE="REFERENCE">Cates 2006</LINK>). In some studies, quaternium agents administered in conjunction with beta 2-agonists have been shown to potentially increase the magnitude and duration of bronchodilation over that achieved with beta 2-agonists alone. A Cochrane review examined this therapy in children (<LINK REF="REF-Plotnik-1998" TYPE="REFERENCE">Plotnik 1998</LINK>). The airway edema and secretions associated with acute asthma are best treated with anti-inflammatories such as corticosteroids (CS) delivered by inhaled, oral, intravenous or intra-muscular routes. However, the timing, route, dose, and target population for CS treatment may vary markedly. The potential role of other agents in the initial management of acute asthma is still unclear. </P>
<P>Despite this general consensus, treatment approaches vary between and within emergency departments, perhaps because of the lack of evidence-based summaries of the research pertinent to this field. For example, there is an unresolved debate about the use of corticosteroids in the early treatment of acute asthma for ED patients (<LINK REF="REF-Engel-1991" TYPE="REFERENCE">Engel 1991</LINK>; <LINK REF="REF-Rowe-1992" TYPE="REFERENCE">Rowe 1992</LINK>). Although previous overviews (<LINK REF="REF-Engel-1991" TYPE="REFERENCE">Engel 1991</LINK>; <LINK REF="REF-Rowe-1992" TYPE="REFERENCE">Rowe 1992</LINK>; <LINK REF="REF-Rowe-1997" TYPE="REFERENCE">Rowe 1997</LINK>) have attempted to clarify the evidence, several new trials have been completed since their publication; an update of the available evidence is needed.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to determine the effect (on admission rate, pulmonary functions [PFTs], physiologic measures, etc.) of any form of systemic corticosteroids (intravenous [IV], intramuscular [IM], oral [OCS]) administered early in the course of treatment for patients presenting to the ED with acute asthma. </P>
<P>Specific Aims: To quantify the effect of the combination of corticosteroids with other agents compared to the effect of these other agents alone. <BR/>The specific outcomes include: <BR/>
</P>
<UL>
<LI>the effect of CS therapy on admission (e.g., time to decision, % admission); </LI>
<LI>the effect of CS therapy on pulmonary functions; and </LI>
<LI>the effect of CS therapy on side effects and vital signs (e.g., heart rate, respiratory rate, and blood pressure).</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-23 15:34:32 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-07-23 15:30:59 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>To be considered, studies had to be randomised controlled trials (RCT) or quasi RCTs (allocation on days of the week, or some other method). </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies including patients of any age (adults, children &gt; 2 years or combined) presenting to an ED were considered for inclusion. If a trial also recruited patients from other settings who could be removed easily from the study (for example if stratified randomisation was employed) the data would be included. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The target intervention was the administration of IV, IM, or oral corticosteroids early (&lt; 1 hour) in the ED treatment. Studies in which patients were admitted to the hospital and later given corticosteroids were excluded. The control intervention was the administration of placebo. Comparison of doses, delivery systems, or agents were included only if a placebo arm was incorporated. Details of co-interventions were recorded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-23 15:30:59 +0100" MODIFIED_BY="Toby J Lasserson">
<P> (Yes/No). Attempts were made to contact the primary investigators of included studies to obtain individual patient data, however this was unsuccessful.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-23 15:30:06 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The primary outcome was admission to hospital. </P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-23 15:30:59 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Lung function </P>
<P>Symptoms</P>
<P>Adverse events </P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-23 15:31:26 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-07-23 15:31:17 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Review Group (ARG) has developed an "Asthma and Wheez* RCT" register through a comprehensive search of EMBASE, MEDLINE, and CINAHL. Hand searching of 20 common respiratory care journals has been completed and relevant RCTs have been added to this register. It is updated regularly with searches of CENTRAL, the Cochrane Collaboration's RCT register. Search of the ARG register was completed using the following terms:<BR/>
</P>
<UL>
<LI>Corticosteroid* OR steroid* OR glucocorticoid* OR prednis* OR solumedrol OR medrol OR dexamethasone OR methylpred* OR solucortef OR decadron AND Emerg* AND Discharge OR admi* OR hospit*.</LI>
</UL>
<P>We did not exclude trials on the basis of language. The current overview includes ARG register updates to January 1999.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-23 15:31:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomised controlled trials were identified in the register using the following search strategy: placebo* OR trial* OR random* OR double-blind OR double blind OR single-blind OR single blind OR controlled study OR comparative study. Additional efforts to locate potential trials were as follows:<BR/>
</P>
<UL>
<LI>Reference lists of all available primary studies were reviewed to identify potentially relevant citations.</LI>
<LI>Inquiries were made regarding other published or unpublished trials known or supported by the authors of the primary studies so that these results could be included in this review.</LI>
<LI>Structured searches of CENTRAL using Corticosteroids AND Asthma.</LI>
<LI>Personal contact with colleagues, collaborators and other trialists working in the field of asthma was made to identify potentially relevant studies.</LI>
<LI>Screening the reference lists of both review articles (<LINK REF="REF-Engel-1991" TYPE="REFERENCE">Engel 1991</LINK>; <LINK REF="REF-Rowe-1992" TYPE="REFERENCE">Rowe 1992</LINK>).</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-23 15:34:32 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-07-23 15:32:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>From the title, abstract, or descriptors, two reviewers (BR, JB) independently reviewed literature searches to identify potentially relevant trials for full review. From the full text, using specific criteria, two reviewers (CS, FD) independently selected trials for inclusion in this review. Agreement was measured using kappa statistics. Disagreement was resolved by consensus or third party adjudication (BR).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-23 15:32:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data for the trials were extracted by two reviewers (BR, JB) and entered into the Cochrane Collaboration software program (Review Manager). Primary study authors were requested to confirm data extraction and provide additional clarification and information for the review. In some cases, point estimates were obtained from expansions of graphic reproductions and calculations from other data presented in the paper.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-23 15:33:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Methodological quality assessment was performed independently by two reviewers using two methods. The first method used the Cochrane approach to assessment of allocation concealment (Grade A: adequate concealment; Grade B: uncertain concealment; Grade C: clearly inadequate concealment). In the second method, each study was assessed independently by two reviewers for validity using a ordinal scale (0-5) described by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). One point is allocated for randomisation, blinding and description of withdrawals and drop-outs; an extra point can be added for methods of randomisation and blinding that are well described and adequate. Studies which use a clearly inadequate method of randomisation or blinding (such as alternating patients) lose the point allocated. The maximum score is five points and studies scoring below three points are usually regarded as being of low methodological quality. For both methods, inter-rater reliability was measured by kappa and weighted kappa statistics, and disagreement was resolved by third party adjudication.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-07-23 15:33:28 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For pooled effects, heterogeneity was tested using the Breslow-Day test; p &lt; 0.05 was be considered statistically significant. Results are reported using a random effects model. In most cases, the results for fixed and random effects model were similar, except where there was significant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-23 15:32:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Trial data were combined using Review Manager. For continuous variables, a random effects weighted mean difference (WMD) or standardised mean difference (SMD) and 95% confidence interval (CI) was calculated for each study. All similar studies were pooled using random effects WMD or SMD and 95% CIs. For dichotomous variables, a random effects odds ratio (OR) with 95% confidence intervals (95% CI) was calculated for individual studies. All similar studies were pooled using random effects OR and 95% CIs.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-23 15:34:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Since significant heterogeneity existed, a series of subgroup analyses were performed (<LINK REF="REF-Oxman-1992" TYPE="REFERENCE">Oxman 1992</LINK>). A priori, these studies were divided on the following basis:<BR/>
</P>
<UL>
<LI>Age: pediatric versus adult (&lt;18 pediatric);</LI>
<LI>Steroid use: previous steroid use vs. no previous steroid use;</LI>
<LI>Severity: severity was based on admission rates in placebo group (severe if admission = or &gt; 40% in the placebo arm or non-severe if admission rate &lt; 40% in the placebo arm);</LI>
<LI>Outcome: assessment scores and time of outcome assessment (2, 4, 6 hours);</LI>
<LI>Intervention: route of administration (IV vs. PO).</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-07-23 15:34:32 +0100" MODIFIED_BY="Toby J Lasserson">
<P>In addition, sensitivity analyses were conducted on fixed effect versus random effects modelling, and methodological quality (high versus low).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-23 15:38:03 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-07-23 15:36:12 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-07-23 15:35:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Eighteen articles were identified by one or both of the reviewers as being potentially relevant. All of these articles were recovered and provided to two different reviewers for independent decision on inclusion. A total of 9 articles were included (kappa: 0.78). Following communication with authors, one additional article was identified (<LINK REF="STD-Connett-1994a" TYPE="STUDY">Connett 1994a</LINK>), and one article was excluded because it dealt with in-hospital treatment (<LINK REF="STD-Deshpande-1986" TYPE="STUDY">Deshpande 1986</LINK>). This search was updated in 1999 and three additional trials were identified (<LINK REF="STD-Lin-1997" TYPE="STUDY">Lin 1997</LINK>; <LINK REF="STD-Lin-1999" TYPE="STUDY">Lin 1999</LINK>; <LINK REF="STD-McFadden-1976" TYPE="STUDY">McFadden 1976</LINK>). An update search conducted in September 2002 did not yield any further trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-23 15:36:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For descriptions of the design of each included study see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>The evidence that corticosteroids prevent admissions when used in early ED asthma care has been the result of research produced within the past 15 years. Since the previous overviews (<LINK REF="REF-Rowe-1992" TYPE="REFERENCE">Rowe 1992</LINK>; <LINK REF="REF-Engel-1991" TYPE="REFERENCE">Engel 1991</LINK>), 6 additional studies have been published (<LINK REF="STD-Scarfone-1993" TYPE="STUDY">Scarfone 1993</LINK>; <LINK REF="STD-Connett-1994a" TYPE="STUDY">Connett 1994a</LINK>; <LINK REF="STD-Wolfson-1994" TYPE="STUDY">Wolfson 1994</LINK>; <LINK REF="STD-Rodrigo-1994" TYPE="STUDY">Rodrigo 1994</LINK>; <LINK REF="STD-Lin-1997" TYPE="STUDY">Lin 1997</LINK>; <LINK REF="STD-Lin-1999" TYPE="STUDY">Lin 1999</LINK>) and 1 additional study was identified (<LINK REF="STD-Deshpande-1986" TYPE="STUDY">Deshpande 1986</LINK>).</P>
<P>Populations: Six (55%) publications specifically examined the use of corticosteroids in adult patients and 5 (45%) involved pediatric patients. Most studies included patients if they exhibited clinical criteria for acute asthma and did not have known chronic medical conditions. Patients receiving systemic corticosteroids prior to the exacerbation were excluded from five studies (<LINK REF="STD-Littenberg-1986" TYPE="STUDY">Littenberg 1986</LINK>; <LINK REF="STD-Storr-1987" TYPE="STUDY">Storr 1987</LINK>; <LINK REF="STD-Tal-1990" TYPE="STUDY">Tal 1990</LINK>; <LINK REF="STD-Scarfone-1993" TYPE="STUDY">Scarfone 1993</LINK>; <LINK REF="STD-Connett-1994a" TYPE="STUDY">Connett 1994a</LINK>; <LINK REF="STD-Wolfson-1994" TYPE="STUDY">Wolfson 1994</LINK>) and sub-grouped in another (<LINK REF="STD-Schneider-1988" TYPE="STUDY">Schneider 1988</LINK>). Exclusions for current inhaled corticosteroid use were less frequently reported, and sub-group analyses could not be performed based on this population separation.</P>
<P>The severity of asthma at presentation was poorly documented, but by inference would be considered "severe". For example, most studies (N = 7; 64%) had placebo arm admissions rates of &gt; 40%. In addition, most studies excluded patients presenting for prescription refills, or with mild asthma. The range of admission rates in the placebo groups was 10 to 97%.</P>
<P>Interventions: The drug type, route of administration and dose varied across studies. Studies examined the use of oral (N = 3), intravenous (N = 7), or intramuscular (N = 1) steroids as a single therapy early in the ED. No studies specifically compared inhaled steroids to a placebo agent; however, two studies which added inhaled steroids to the systemic CS without a placebo arm were excluded (<LINK REF="STD-Scarfone-1995" TYPE="STUDY">Scarfone 1995</LINK>; <LINK REF="STD-Guttman-1997" TYPE="STUDY">Guttman 1997</LINK>).</P>
<P>While the dose of steroids varied, all protocols required the corticosteroids to be administered "early" (between 30-45 minutes post arrival). In adults, solucortef (N = 1) or solumedrol (N = 5) was used in doses of 500 mg and 125 mg intravenously, respectively. Oral therapy only occurred in children, and consisted of doses of 1-2 mg/kg of prednisone or prednisolone. All doses would be considered "high" (<LINK REF="REF-Manser-1998" TYPE="REFERENCE">Manser 1998</LINK>).</P>
<P>Co-interventions: Different co-interventions were provided. Variable approaches to beta2-agonist delivery were reported; most patients received nebulised therapy, but one study did use MDI + spacer (<LINK REF="STD-Rodrigo-1994" TYPE="STUDY">Rodrigo 1994</LINK>). Studies permitted flexible (N = 2: <LINK REF="STD-Littenberg-1986" TYPE="STUDY">Littenberg 1986</LINK>; <LINK REF="STD-Wolfson-1994" TYPE="STUDY">Wolfson 1994</LINK>) or insisted on rigorous (N = 9) dosing schedules for the in-ED beta2-agonists and other co-interventions. Theophylline use was routine in two studies (<LINK REF="STD-Littenberg-1986" TYPE="STUDY">Littenberg 1986</LINK> - IV; <LINK REF="STD-Stein-1990" TYPE="STUDY">Stein 1990</LINK> - oral) and administered to "failures" in one study (<LINK REF="STD-Schneider-1988" TYPE="STUDY">Schneider 1988</LINK>). The use of anticholinergic agents in addition to beta2-agonists was rarely reported (<LINK REF="STD-Lin-1999" TYPE="STUDY">Lin 1999</LINK>).</P>
<P>Outcomes: A variety of outcome measures were reported. Hospital discharge or admission were the most common (11/12 studies); however, the criteria for admission/discharge and timing of decision varied considerably. In addition, several pulmonary function test outcomes (PEFR, FEV-1, FVC, % predicted PEFR, % predicted FEV-1, etc) were used to measure treatment effect but there was no consistent format for reporting. A pooled estimate was obtained using the final study measurement for % PEFR and PEFR using an SMD. Infrequently, symptom scores were reported as outcomes. Due to the variation in scales and scores used, no pooled analysis was possible for symptoms. Finally, side-effects (e.g., nausea, headache, tremor) were occasionally reported also.</P>
<P>Confirmation of data: We attempted to contact all authors to request confirmation of methods and data extraction and provide additional clarification and information for the review. While many authors responded, unfortunately, most could not access their original data source to perform supplemental analyses. Wherever possible, expansions of graphic reproductions and estimations were used.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-07-23 15:36:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Many of the studies were double-blind, all were placebo controlled, demonstrated an appreciation of the need for concealment of allocation, and reported a sufficient number of outcomes. The methodological quality of all studies, using the Jadad method, was rated as "high" (scores =&gt; 3). Using the Cochrane method, 5 studies (<LINK REF="STD-Littenberg-1986" TYPE="STUDY">Littenberg 1986</LINK>; <LINK REF="STD-Schneider-1988" TYPE="STUDY">Schneider 1988</LINK>; <LINK REF="STD-Tal-1990" TYPE="STUDY">Tal 1990</LINK>; <LINK REF="STD-Connett-1994a" TYPE="STUDY">Connett 1994a</LINK>; <LINK REF="STD-Wolfson-1994" TYPE="STUDY">Wolfson 1994</LINK>) were rated as having blinded allocation and 7 studies (<LINK REF="STD-McFadden-1976" TYPE="STUDY">McFadden 1976</LINK>; <LINK REF="STD-Storr-1987" TYPE="STUDY">Storr 1987</LINK>; <LINK REF="STD-Stein-1990" TYPE="STUDY">Stein 1990</LINK>; <LINK REF="STD-Scarfone-1993" TYPE="STUDY">Scarfone 1993</LINK>; <LINK REF="STD-Rodrigo-1994" TYPE="STUDY">Rodrigo 1994</LINK>; <LINK REF="STD-Lin-1997" TYPE="STUDY">Lin 1997</LINK>; <LINK REF="STD-Lin-1999" TYPE="STUDY">Lin 1999</LINK>) were rated as having unclear allocation concealment.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-23 15:38:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Pooling of data was carried out because the populations, interventions and outcomes were similar. Despite this, significant heterogeneity was identified in the pooled analyses so results are presented with the pooled data followed by subgroup analyses.</P>
<SUBSECTION>
<HEADING LEVEL="5">Main Comparison: Corticosteroids versus Placebo</HEADING>
<P>Eleven of the 12 included studies provided sufficient information for pooling hospital admission rates. Most studies (9/11) provided a point estimate in favor of treatment with CS. Four studies demonstrated a statistically significant difference in favor of CS treatment, while no studies demonstrated a benefit with placebo treatment. Using a random effects model, the overall result suggests a significant reduction in admission following the early use of corticosteroids in ED asthma treatment (n = 11; pooled OR: 0.50, 95% CI: 0.31, 0.81, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). This would correspond with a number needed to treat (NNT) of 8 (95% CI: 5 to 21). However, heterogeneity was demonstrated in this pooled estimate (chi square = 21.3; df = 11; p &lt; 0.05). As planned, the following subgroup analyses were performed to identify the source of the heterogeneity.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup Analyses</HEADING>
<P>Use of Systemic Steroids: Because the regular use of systemic corticosteroids in the days and weeks preceding the index visit could be a potential confounder, a subgroup analysis based on previous CS therapy was completed. When only studies involving patients not receiving systemic CS prior to ED presentation were considered, early ED CS therapy appeared effective (N = 7; OR: 0.37, 95% CI: 0.19 to 0.70). This would correspond with a number needed to treat of 6 (95% CI: 4 to 11). However, heterogeneity existed in this pooled analysis (chi square = 15.21; df = 7; p &lt; 0.05). In studies with mixed populations the early use of CS in the ED appeared to be less effective (N = 5; OR: 0.82; 95% CI: 0.48 to 1.4), without significant heterogeneity (chi square = 3.53; df = 4; p &gt; 0.1).</P>
<P>Severity of Disease: In the absence of any consistent application of PFT results to determine disease severity, the rate of admission in the placebo group was used as a proxy severity measure. Most studies (N = 7; 64%) had admission rates &gt; 40%. When trials were stratified using this cut-off, trials with a high baseline admission rates experienced a significant reduction in admissions following early CS use (N = 7; OR: 0.35, 95% CI: 0.21 to 0.59) compared to those studies with lower severity (N = 4; OR: 1.21, 95% CI: 0.66 to 2.22). The pooled results were homogeneous for both the severe (chi square = 11.2; df = 7; p &gt; 0.1) and non-severe (chi square = 1.4; df = 3; p &gt; 0.1) groups. These results would correspond with a number needed to treat of 5 (95% CI: 4 to 7) in the severe group.</P>
<P>Age Subgroup: There did not appear to be any difference in the magnitude of the reduction in admission rate due to early CS use between studies of children (n = 5; OR: 0.40, 95% CI: 0.17 to 0.94) or adults (n = 6; OR: 0.58, 95% CI: 0.32 to 1.07). The pooled results were homogeneous for adults but not for children (chi square = 13.65; df = 5; p &lt; 0.025).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analyse</HEADING>
<P>Timing of Outcome Assessment: Since steroids are believed to exert their effect over hours rather than minutes, one would expect a greater reduction in admission rate with longer ED treatment times. The sensitivity analysis confirmed this theory. However, few trialists could provide additional time data, and these results should be interpreted cautiously. The early outcomes (&lt;= 2 hours) were not significant (N = 2; OR: 1.38, 95% CI: 0.41 to 4.67), whereas a benefit with CS therapy was demonstrated at 4 hours (n = 5; OR: 0.48, 95% CI: 0.24 to 0.97) and 6 hours (N = 7; OR: 0.28, 95% CI: 0.09 to 0.84) after administration. Significant heterogeneity (chi square = 17.7; df = 6; p &lt; 0.01) was demonstrated for the 6 hour pooled results.</P>
<P>Route of Administration: Although no direct comparison of routes of administration could be made, the magnitude of the reduction in admission rates appeared greater with the oral routes (N = 3; OR: 0.24, 95% CI: 0.11 to 0.53) than IV (N = 7; OR: 0.68, 95% CI: 0.39 to 1.21) routes. The oral corticosteroid analysis did not demonstrate heterogeneity (p &gt; 0.1) while the IV analysis did (chi square = 11.9; df = 6; p &lt; 0.1). Whilst these results suggest at first sight that oral therapy may be more effective, it should be recalled that this route was only used in the treatment of children, whereas IV therapy was used in children and adults.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other Outcomes</HEADING>
<P>Pulmonary Functions: The most commonly and consistently reported pulmonary function data were PEFR and % predicted PEFR. The PEFR data were pooled using a SMD for the trials reporting end-of treatment results. The analysis indicated a moderate effect of corticosteroids on PEFR (N = 7; SMD: 0.54; 95% CI: 0.01 to 1.1) with persistent heterogeneity (chi square = 49.25; df = 7; p &lt; 0.001).</P>
<P>Adverse Reactions: Side effect monitoring was uncommon in these studies, and few adverse events were reported. Nausea (N = 2; OR = 0.48; 95% CI: 0.1 to 2.4), tremor (N = 4; OR = 0.82; 95% CI: 0.45 to 1.48), and headache (N = 2; OR = 1.04; 95% CI: 0.26 to 4.2) were similar in frequency; all pooled side effect results demonstrated homogeneity. An insufficient number of studies were available to provide meaningful sensitivity comparisons.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-23 15:07:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>This systematic review summarises the latest evidence derived from randomised controlled trials for the early use of corticosteroids in the treatment of acute asthma in the ED setting. Overall, the results of this review indicate that patients who were treated with systemic corticosteroids within one hour of presentation to the emergency department were significantly less likely to be admitted to hospital. This benefit was not apparent for the first two hours of therapy and maximal at 6 hours. Thus, there appears to be benefit in delaying a decision to admit until 4-6 hours after CS therapy. Subgroup analysis suggests that patients with a greater likelihood of admission (i.e. the more severe) and those not recently treated with oral CS appeared to benefit most.</P>
<P>Oral therapy appears to be effective in children and in a comparison in children, oral and IV therapy were found to be equally effective (<LINK REF="STD-Barnett-1997" TYPE="STUDY">Barnett 1997</LINK>). It is not possible to comment on the efficacy of oral steroids used in adults, since all trials in this age group used the IV route. Similarly, no conclusions can be drawn about dose-response effects, since all steroid doses were high.</P>
<P>Secondary analyses from pulmonary function data suggest that the benefit of corticosteroids is demonstrable by the measurement of the final PEFR or % predicted PEFR. The benefit represents a range of possible improvements in PFT, which also appears to be a clinically important improvement (<LINK REF="REF-Tiffany-1993" TYPE="REFERENCE">Tiffany 1993</LINK>).</P>
<P>Within the time course of this study, these doses of steroids did not appear to cause more tremor, headache or nausea than placebo.</P>
<P>The number needed to treat (NNT) with corticosteroids compared to placebo to prevent one admission is 5 (95% CI: 4 to 7) for an admission rate of &gt; 40% in the placebo arm. Alternatively, the NNT is higher and not statistically significant if the admission rate is low (&lt; 20%) in the placebo arm. Since corticosteroids are inexpensive, readily available, and their safety in single-dose or short term therapy is accepted, early treatment using these drugs for most asthmatics would be prudent. This recommendation is in keeping with that provided by the Canadian Association of Emergency Physicians (CAEP; <LINK REF="REF-Beveridge-1996" TYPE="REFERENCE">Beveridge 1996</LINK>), national asthma plan in the US (<LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>), and British Thoracic Society (BTS; <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>); all of whom recommend systemic corticosteroids for patients with acute asthma.</P>
<P>Methodological Limitations<BR/>Due to the heterogeneity of the pooled results in this meta-analysis and the overall small number of patients upon which the subgroup results are based, subgroup analyses need to be interpreted with caution (<LINK REF="REF-Oxman-1992" TYPE="REFERENCE">Oxman 1992</LINK>). However, the overall findings would seem to apply to all patients with acute asthma presenting to the ED setting.</P>
<P>There is a possibility of publication bias or study selection bias in this meta-analysis. For example, by not identifying unpublished negative trials we may be over-estimating the effect of corticosteroid treatment. A comprehensive search of the published literature for potentially relevant studies was conducted, using a systematic strategy and objective inclusion criteria to avoid such biases. This was followed by attempts to contact corresponding and first authors. No unpublished or negative trials were uncovered, however we recognise that they may exist. In addition, examination of the funnel plots (OR vs. Sample size/weight) indicates symmetry, thus suggesting publication bias was unlikely.</P>
<P>Several other methodological issues limit the applicability of the results of this review. The admission rate for the placebo arms of these trials varied from 10% to 97%; 7 trials had admission rates above 40%. These rates are higher than expected and certainly higher than the 10 to 20% quoted in large multicenter studies in US and Canada (<LINK REF="REF-Camargo-1998a" TYPE="REFERENCE">Camargo 1998a</LINK>; <LINK REF="REF-Camargo-1998b" TYPE="REFERENCE">Camargo 1998b</LINK>). Since the subgroup analyses suggested a possible effect of severity on response to CS, this is an important area for future research. While the criteria for admission were variable or poorly documented, this does appear to be a clinically valuable measure of asthma outcome. Rigorous standardisation of this outcome would improve study comparability. For now, the results of this review apply to patients with severe asthma.</P>
<P>Evaluation of pulmonary function data was complicated by a lack of standardised reporting and changing analyses within the reports. For example, PFT analyses often changed from comparisons of treatment vs. control at the start of the study, to comparisons between admitted and non-admitted groups at the end. This precluded more formal evaluation of the effects of the interventions based on PFTs and also the effects of the intervention on PFTs at follow-up.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This overview reconfirms evidence from earlier systematic reviews (<LINK REF="REF-Rowe-1992" TYPE="REFERENCE">Rowe 1992</LINK>; <LINK REF="REF-Engel-1991" TYPE="REFERENCE">Engel 1991</LINK>) and supports the use of steroids for treatment of emergency department patients assessed with acute asthma. Therapy with high dose systemic steroids should be commenced within one hour of presentation to the emergency department. Unless the patients failed to respond to early therapy, deteriorated or gave other reasons for concern, a decision whether to admit may be usefully delayed until 6 hours after treatment. In children, oral therapy appears to be very effective, although there are no data to provide guidance as to the efficacy of oral therapy for adults in this setting.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further studies in this area will need to consider the results of the subgroup analyses. Studies which stratify patients into those recently receiving oral steroids vs those receiving maintenance inhaled steroids would seem appropriate. Documentation of asthma severity at presentation needs to be standardised to permit generalisability of trial results. Standardised assessment times would also be useful. A better description of admission criteria is required.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to acknowledge the assistance of Stephen Milan, Jane Dennis, and Anna Bara of the Cochrane Airways Review Group. We would also like to acknowledge the assistance of the following corresponding authors: Dr. Randolphe Cole, Dr. Sandra Schneider, Dr. Gail Shapiro, Dr. Richard Scarfone, Dr. Warren Lenney, Dr. Asher Tal, and Dr. David Wolfson. Finally, the assistance of Prof. Paul Jones (ARG Editor) in reviewing the manuscript was greatly appreciated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors who have been involved in this review have done so without any known conflicts of interest. They are not involved with the primary studies. Dr. Rowe has received unrestricted educational grants for research from Astra, Janssen-Ortho, Boehringer-Ingelheim, Forest, Glaxo, Merck, and Sepracor. Dr. Ducharme has received support from Boehringer-Ingelheim. However, none of the authors are considered paid consultants by any pharmaceutical company that produces CS agents. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Rowe BH: initiated review, wrote protocol and funding application, completed searches and selection, completed data entry and analysis, principal author and assigned ARG editor.<BR/>Spooner C: contributed to protocol, study selection, completed quality assessment, performed editing and manuscript review, and converted final review to RevMan4.<BR/>Ducharme FM: contributed to protocol, contributed to study selection and quality assessment, and completed manuscript review.<BR/>Bretzlaff JA : contributed to protocol, completed searches and study selection, completed data extraction and entry, and manuscript review.<BR/>Bota GW: contributed to protocol, study selection and manuscript review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2008-07-23 15:03:51 +0100" MODIFIED_BY="Toby J Lasserson">
<INCLUDED_STUDIES MODIFIED="2008-07-23 15:03:51 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Connett-1994a" NAME="Connett 1994a" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Connett GJ, Warde C, Wooler E, Lenney W.  Prednisolone and salbutamol in the hospital treatment of acute asthma.  Arch Dis Child 1994;70:170-173.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connett GJ, Warde C, Wooler E, Lenney W</AU>
<TI>Prednisolone and salbutamol in the hospital treatment of acute asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1994</YR>
<VL>70</VL>
<PG>170-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connett-1994b" NAME="Connett 1994b" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Connett GJ, Warde C, Wooler E, Lenney W.  Prednisolone and salbutamol in the hospital treatment of acute asthma.  Arch Dis Child 1994;70:170-173.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connett GJ, Warde C, Wooler E, Lenney W</AU>
<TI>Prednisolone and salbutamol in the hospital treatment of acute asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1994</YR>
<VL>70</VL>
<PG>170-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1997" NAME="Lin 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin RY, Pesola GR, Westfal RE, Bakalchuk L, Freyberg CW, Cataquet D, et al</AU>
<TI>Early parenteral corticosteroid administration in acute asthma</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>621-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1999" NAME="Lin 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Lin RY, Pesola GR, Bakalchuk L, Heyl GT, Dow AM, Tenenbaum C, Curry A, Westfal RE.  Rapid improvement of peak flow in asthmatic patients treated wih parenteral methylprednisolone in the emergency department: A randomized controlled study. Ann of Emerg Med 1999;33:487-494.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin RY, Pesola GR, Bakalchuk L, Heyl GT, Dow AM, Tenenbaum C, et al</AU>
<TI>Rapid improvement of peak flow in asthmatic patients treated wih parenteral methylprednisolone in the emergency department: A randomized controlled study</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>5</NO>
<PG>487-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Littenberg-1986" NAME="Littenberg 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Littenberg B, Gluck E.  A controlled trial of methylprednisolone in the emergency treatment of acute asthma.  N Eng J Med 1986;150-152.&lt;br&gt;Littenberg B. Gluck EH. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. [Clinical Trial. Journal Article.&lt;br&gt;Randomized Controlled Trial] New England Journal of Medicine. 314(3):150-2, 1986 Jan 16. &lt;br&gt;UI: 3510384&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Littenberg B, Gluck E</AU>
<TI>A controlled trial of methylprednisolone in the emergency treatment of acute asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>3</NO>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFadden-1976" NAME="McFadden 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;McFadden ER Jr, Kiser R, deGroot WJ, Holmes B, Kiker R, Viser G.  A controlled study of the effects of single doses of hydrocortisone on the resolution of acute attacks of asthma.  Am J Med. 1976 Jan;60(1):52-9. PMID: 766619 [PubMed - indexed for MEDLINE]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFadden ER Jr, Kiser R, deGroot WJ, Holmes B, Kiker R, Viser G</AU>
<TI>A controlled study of the effects of single doses of hydrocortisone on the resolution of acute attacks of asthma</TI>
<SO>American Journal of Medicine</SO>
<YR>1976</YR>
<VL>60</VL>
<NO>1</NO>
<PG>52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodrigo-1994" MODIFIED="2008-07-23 15:03:51 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rodrigo 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-07-23 15:03:51 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Rodrigo C, Rodrigo G.  Early administration of hyrdrocortisone in the emergency room treatment of acute asthma:  A controlled clinical trial.  Resp Med 1994;88:755-761.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:03:51 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigo C, Rodrigo G</AU>
<TI>Early administration of hydrocortisone in the emergency room treatment of acute asthma: A controlled clinical trial</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>755-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scarfone-1993" NAME="Scarfone 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Sarfone RJ, Fuchs SM, Nager AL, Shane SA.  Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.  Pediatrics 1993;92:513-518.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarfone RJ, Fuchs SM, Nager AL, Shane SA</AU>
<TI>Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>513-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1988" NAME="Schneider 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Schneider SM, Pipher A, Britton HL, Borok Z, Harcup CH.  High-dose methylprednisolone as initial therapy in patients with acute bronchospasm.  J Asthma 1988;25:189-193.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider SM, Pipher A, Britton HL, Borok Z, Harcup CH</AU>
<TI>High-dose methylprednisolone as initial therapy in patients with acute bronchospasm</TI>
<SO>Journal of Asthma</SO>
<YR>1988</YR>
<VL>25</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1990" NAME="Stein 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Stein LM, Cole RP.  Early administration of corticosteroids in emergency room treatment of acute asthma.  Ann Intern Med 1990;112:822-827.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein LM, Cole RP</AU>
<TI>Early administration of corticosteroids in emergency room treatment of acute asthma</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1990</YR>
<VL>112</VL>
<PG>822-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Storr-1987" NAME="Storr 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Storr J, Barrel E, Barry W, Lenney W, Hatcher G.  Effect of a single oral dose of prednisolone in acute childhood asthma.  Lancet 1987;879-881.&lt;br&gt;Storr J. Barrell E. Barry W. Lenney W. Hatcher G. Effect of a single oral dose of prednisolone in acute childhood asthma. [Clinical Trial. Journal Article.&lt;br&gt;Randomized Controlled Trial] Lancet. 1(8538):879-82, 1987 Apr 18. UI: 2882288&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storr J, Barrel E, Barry W, Lenney W, Hatcher G</AU>
<TI>Effect of a single oral dose of prednisolone in acute childhood asthma</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>8538</NO>
<PG>879-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-1990" NAME="Tal 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Tal A, Levy N, Bearman JE.  Methylprednisolone therapy for acute asthma in infants and toddlers: A controlled clinical trial.  Pediatrics 1990;86:350-356.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Levy N, Bearman JE</AU>
<TI>Methylprednisolone therapy for acute asthma in infants and toddlers: A controlled clinical trial</TI>
<SO>Pediatrics</SO>
<YR>1990</YR>
<VL>86</VL>
<PG>350-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfson-1994" NAME="Wolfson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Wolfson DH, Nypaver MM, Blaster M, Hogan A, Evans R, Davis T.  A controlled trial of methylprednisolone in the early emergency department treatment of acute asthma in children.  Ped Emerg Care 1994;10:335-338.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfson DH, Nypaver MM, Blaster M, Hogan A, Evans R, Davis T</AU>
<TI>A controlled trial of methylprednisolone in the early emergency department treatment of acute asthma in children</TI>
<SO>Pediatric Emergency Care</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>335-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-23 15:03:40 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Afilalo-1999" NAME="Afilalo 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Afilalo M, Guttman A, Colacone A, Dankoff J, Tselios C, Stern E et al. Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department:  A randomized clinical trial. Ann Emerg Med 1999; 33(3):304-309.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Afilalo M, Guttman A, Colacone A, Dankoff J, Tselios C, Stern E, et al</AU>
<TI>Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: A randomized clinical trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>3</NO>
<PG>304-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnaud-1982" NAME="Arnaud 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Arnaud A, Charpin J.  Interaction between corticosteroids and beta-2-agonists in acute asthma.  Eur J Respir Dis 1982;122:126-131.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnaud A, Charpin J</AU>
<TI>Interaction between corticosteroids and beta-2-agonists in acute asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnett-1997" NAME="Barnett 1997" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Barnett PL, Caputo GL, Baskin M, Kupperman N. Intravenous versus oral corticosteroids in the management of acute asthma in children.  Ann Emerg Med 1997;29:212-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnett PL, Caputo GL, Baskin M, Kupperman N</AU>
<TI>Intravenous versus oral corticosteroids in the management of acute asthma in children</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1997</YR>
<VL>29</VL>
<PG>212-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deshpande-1986" MODIFIED="2008-07-23 15:03:40 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Deshpande 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-07-23 15:03:40 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Deshpande A, McKenzie SA. Short course of steroids in home treatmnent of children with acute asthma.  Br Med J (Clin Res Ed) 1986; 293:169-171.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:03:40 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deshpande A, McKenzie SA</AU>
<TI>Short course of steroids in home treatment of children with acute asthma</TI>
<SO>British Medical Journal (Clin Res Ed)</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>169-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanta-1983" NAME="Fanta 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Fanta CH, Rossing TH, McFadden ER Jr.  Glucocorticoids in acute asthma.  Amer J Med 1983;71:845-851.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fanta CH, Rossing TH, McFadden ER Jr</AU>
<TI>Glucocorticoids in acute asthma</TI>
<SO>American Journal of Medicine</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>845-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guttman-1997" NAME="Guttman 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Guttman A, et al.  The effects of combined intravenous and inhaled steroids (Beclomethasone Diproprionate) for the emergency treatment of acute asthma.  Acad Emerg Med 1997;4:100-106.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guttman A, Afilalo M, Colacone A, Kreisman H, Dankoff J</AU>
<TI>The effects of combined intravenous and inhaled steroids (Beclomethasone Diproprionate) for the emergency treatment of acute asthma</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klig-1997" MODIFIED="2008-07-23 15:03:35 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Klig 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-23 15:03:35 +0100" MODIFIED_BY="Toby J Lasserson" NOTES="&lt;p&gt;Klig JE, Hodge D, Rutherford MW. Symptomatic improvement following emergency department management of asthma: A pilot study of intamuscular dexamethasone versus oral prednisone.  J Asthma 1997;34:419-425.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:03:35 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klig JE, Hodge D, Rutherford MW</AU>
<TI>Symptomatic improvement following emergency department management of asthma: A pilot study of intramuscular dexamethasone versus oral prednisone</TI>
<SO>Journal of Asthma</SO>
<YR>1997</YR>
<VL>34</VL>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morray-1995" NAME="Morray 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Morray B, Redding G.  Factors associated with prolonged hospitalization of children with asthma.  Arch Pediatr Adolesc 1995;149:276-279.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morray B, Redding G</AU>
<TI>Factors associated with prolonged hospitalization of children with asthma</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1995</YR>
<VL>149</VL>
<PG>276-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogirala-1991" NAME="Ogirala 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Ogirala RG, Aldrich TK, Prezant DJ, Sinnet MJ, Enden JB, Williams MH.  High-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma.  N Eng J Med 1991;324:585-589.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogirala RG, Aldrich TK, Prezant DJ, Sinnet MJ, Enden JB, Williams MH</AU>
<TI>High-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>585-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pansegrouw-1992" NAME="Pansegrouw 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Pansegrouw DF.  Acute resistant asthma caused by excessive beta-2-adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone.  S Afr Med J 1992 82:179-182.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pansegrouw DF</AU>
<TI>Acute resistant asthma caused by excessive beta-2-adrenoceptor agonist inhalation and reversed by inhalation of beclomethasone</TI>
<SO>South African Medical Journal</SO>
<YR>1992</YR>
<VL>82</VL>
<PG>179-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodrigo-1998" NAME="Rodrigo 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Rodrigo G, Rodrigo C.  Inhaled flunisolide for acute severe asthma.  Am J Respir Crit Care Med 1998;157:698-703.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigo G, Rodrigo C</AU>
<TI>Inhaled flunisolide for acute severe asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<PG>698-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scarfone-1995" NAME="Scarfone 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Scarfone RJ, Loiselle JM, Wiley JF, Decker JM, Henretig FM, Joffe MD.  Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children.  Ann Emerg Med 1995;26:480-86.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scarfone RJ, Loiselle JM, Wiley JF, Decker JM, Henretig FM, Joffe MD</AU>
<TI>Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>480-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuckerman-1998" NAME="Schuckerman 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Schuckerman H, DeJulius DP, Blanda M, Gerson LW, DeJulius AJ, Rajaratnam M. Compariosn of intramuscular triamcinolone and oral prednisone in the out-atient treatment of acute asthma: A randomized controlled trial.  Ann Emerg med 1998;31:333-338.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuckerman H, DeJulius DP, Blanda M, Gerson LW, DeJulius AJ, Rajaratnam M</AU>
<TI>Comparison of intramuscular triamcinolone and oral prednisone in the out-patient treatment of acute asthma: A randomized controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1998</YR>
<VL>31</VL>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1983" NAME="Shapiro 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Shapiro GG, Furukawa CT, Pierson WE, Gardinier R, Bierman CW.  Double-blind evlauation of methyl- prednisolone versus placebo for acute asthma episodes.  Pediatrics 1983;71:510-514.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Furukawa CT, Pierson WE, Gardinier R, Bierman CW</AU>
<TI>Double-blind evaluation of methyl-prednisolone versus placebo for acute asthma episodes</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>510-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Sung-1997" NAME="Sung 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Sung L, Osmond MH, Klassen TP.  Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.  Acad Emerg Med 1998;5:209-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sung L, Osmond MH, Klassen TP</AU>
<TI>Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volovitz-1998" NAME="Volovitz 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department:  A controlled comparative study with oral prednisolone. J All Clin Immun 1998; 102:605-609.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, et al</AU>
<TI>Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: A controlled comparative study with oral prednisolone</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>102</VL>
<PG>605-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Beveridge-1996" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Beveridge 1996" NOTES="&lt;p&gt;Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR.  Guidelines for the emergency management of asthma in adults.  Can Med Assoc J 1996;155:25-37.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR</AU>
<TI>Guidelines for the emergency management of asthma in adults</TI>
<SO>Canadian Medical Association Journal (CMAJ)</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>25-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" NOTES="&lt;p&gt;(BTS) British Thoracic Sociaty.  The British guidelines on asthma management: 1995 review and position statement.  Thorax 1997;52:152-156.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>(BTS) British Thoracic Sociaty</AU>
<TI>The British guidelines on asthma management: 1995 review and position statement</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>152-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camargo-1998a" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Camargo 1998a" NOTES="&lt;p&gt;Camargo CA, Jr., on behalf of the MARC investigators. Acute asthma among children presenting to the emergency department:  The Multicentre Asthma Research Collaboration [abstract]. Acad Emerg Med 1998; 5:380.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Camargo CA, Jr (on behalf of the MARC investigators)</AU>
<TI>Acute asthma among children presenting to the emergency department: The Multicentre Asthma Research Collaboration</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>380 [abstract]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camargo-1998b" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Camargo 1998b" NOTES="&lt;p&gt;Camargo CA Jr, on behalf of the MARC Investigators. Management of acute asthma in US emergency departments: The Multicenter Asthma Research Collaboration [abstract]. Amer J Resp Crit Care Med 1998;157.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Camargo CA Jr (on behalf of the MARC Investigators)</AU>
<TI>Management of acute asthma in US emergency departments: The Multicenter Asthma Research Collaboration</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1998</YR>
<PG>157 [abstract]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2006" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Cates 2006" NOTES="&lt;p&gt;Cates C. Comparison of holding chambers and nebulisers for beta-agonists in acute asthma (Cochrane Review). In: Cochrane Library, Issue 3. 1998. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Crilly JA, Rowe BH</AU>
<TI>Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-23 15:03:15 +0100" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2008-07-23 15:03:15 +0100" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE=" 14651858. CD000052.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chapman-1991" NAME="Chapman 1991" NOTES="&lt;p&gt;Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma.  N Engl J Med 1991;324:788-794.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chapman KR, Verbeek PR, White JG, Rebuck AS</AU>
<TI>Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>788-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-1999" NAME="Edmonds 1999" NOTES="&lt;p&gt;Edmonds ML, Cmargo CA Jr, Pollack CV Jr, Rowe BH. Inhaled corticosteroids for acute asthma in the emergency department (Cochrane Protocol). In: Cochrane Library, Issue 1. 1999. Oxford: Update Software.&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH</AU>
<TI>Inhaled corticosteroids for acute asthma in the emergency department (Cochrane Protocol)</TI>
<SO>Cochrane Library</SO>
<YR>1999</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engel-1991" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Engel 1991" TYPE="JOURNAL_ARTICLE">
<AU>Engel T, Heinig JH</AU>
<TI>Glucocorticoid therapy in acute severe asthma - A critical review</TI>
<SO>European Respiratory Journal</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-1990" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Fitzgerald 1990" NOTES="&lt;p&gt;Fitzgerald JM, Hargreaves FE. Acute asthma: Emergency department management and prospective evaluation of outcome. Can Med Assoc J 1990;142:591-595.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald JM, Hargreaves FE</AU>
<TI>Acute asthma: Emergency department management and prospective evaluation of outcome</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1990</YR>
<VL>142</VL>
<PG>591-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ.  Assessing the quailty of reports of randomized clinical trials: is blinding necessary? Cont Clin Trials 1996;17:1-12.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quailty of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Littenburg-1988" NAME="Littenburg 1988" NOTES="&lt;p&gt;Littenberg B.  Aminophylline treatment in severe acute asthma:  A meta-analysis.  JAMA 1988; 259:1678-1684.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Littenberg B</AU>
<TI>Aminophylline treatment in severe acute asthma: A meta-analysis</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>1678-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannino-1998" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mannino 1998" NOTES="&lt;p&gt;Mannino DM. Homa DM. Pertowski CA. Ashizawa A. Nixon LL. Johnson CA. Ball LB. Jack E. Kang DS. Surveillance for asthma--United States, 1960-1995. [Journal Article] Morbidity &amp;amp; Mortality Weekly Report. CDC Surveillance Summaries. 47(1):1-27, 1998 Apr 24.  UI: 9580746&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Mannino DM, Homa DM, Pertowski, CA, Ashizawa A, Nixon LL, Johnson CA, et al</AU>
<TI>Surveillance for asthma - United States, 1960-1995</TI>
<SO>Morbidity &amp; Mortality Weekly Report. CDC Surveillance Summaries</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>1-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manser-1998" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Manser 1998" NOTES="&lt;p&gt;Manser R, Reid D,  Abramson M.  The efficacy of varying doses of corticosteroids in the management of hospitalised patients with acute asthma: A systematic review (Review).  In: The Cochrane Library, Issue 3, 1998.  Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="COCHRANE_REVIEW">
<AU>Manser R, Reid D, Abramson M</AU>
<TI>The efficacy of varying doses of corticosteroids in the management of hospitalised patients with acute asthma: A systematic review</TI>
<SO>The Cochrane Library</SO>
<YR>1998</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NAEPP-1997" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NAEPP 1997" TYPE="CONFERENCE_PROC">
<AU>National Asthma Education Program</AU>
<TI>Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. 1997</TI>
<SO>National Institutes of Health</SO>
<YR>1997</YR>
<CY>Bethesda, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oxman-1992" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Oxman 1992" NOTES="&lt;p&gt;Oxman AD, Guyatt GH.  A consumer's guide to subgroup analyses.  Ann Intern Med 1992;116:78-84.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Oxman AD, Guyatt GH</AU>
<TI>A consumer's guide to subgroup analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>116</VL>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plotnik-1998" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Plotnik 1998" NOTES="&lt;p&gt;Plotnik LH, Ducharme FM.  Efficacy and safety of combined inhaled anticholinergics and beta-2-agonists in the initial management of acute pediatric asthma (Cochrane Review).  In: The Cochrane Library, Issue 3, 1998.  Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="COCHRANE_REVIEW">
<AU>Plotnik LH, Ducharme FM</AU>
<TI>Efficacy and safety of combined inhaled anticholinergics and beta-2-agonists in the initial management of acute pediatric asthma</TI>
<SO>The Cochrane Library</SO>
<YR>1998</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-1992" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rowe 1992" NOTES="&lt;p&gt;Rowe BH, Keller J, Oxman AD. Steroid use in the emergency department treatment of asthma exacerbations: A meta-analysis. Amer J of Emerg Med 1992;10:301-310.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Rowe BH, Keller J, Oxman AD</AU>
<TI>Steroid use in the emergency department treatment of asthma exacerbations: A meta-analysis</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>301-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-1997" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rowe 1997" NOTES="&lt;p&gt;Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. The effectiveness of corticosteroids in the treatment of acute exacerbations of asthma: a meta-analysis of their effect on relapse following acute assessment (Cochrane Review). In: Cochrane Library, Issue 2. 1997. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="COCHRANE_REVIEW">
<AU>Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW</AU>
<TI>The effectiveness of corticosteroids in the treatment of acute exacerbations of asthma: a meta-analysis of their effect on relapse following acute assessment</TI>
<SO>Cochrane Library</SO>
<YR>1997</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-1999" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Rowe 1999" NOTES="&lt;p&gt;Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J.  Inhaled budesonide in addition to oral steroids to prevent asthma relapse following discharge from the emergency department: A randomized controlled trial. JAMA 1999;281:2119-2126.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J</AU>
<TI>Inhaled budesonide in addition to oral steroids to prevent asthma relapse following discharge from the emergency department: A randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<PG>2119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-1990" NAME="Stein 1990" NOTES="&lt;p&gt;Stein LM, Cole RP. Early administration of corticosteroids in emergency room treatment of acute asthma. Arch Intern Med 1990;112:822-827.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stein LM, Cole RP</AU>
<TI>Early administration of corticosteroids in emergency room treatment of acute asthma</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1990</YR>
<VL>112</VL>
<PG>822-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tiffany-1993" MODIFIED="2008-07-23 15:36:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Tiffany 1993" NOTES="&lt;p&gt;Tiffany BR, Berk WA, Todd IK, White SR.  Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations.  Chest 1993;104:831-834.&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 15:36:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Tiffany BR, Berk WA, Todd IK, White SR</AU>
<TI>Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>831-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-23 15:04:33 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-23 15:04:33 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Connett-1994a">
<CHAR_METHODS>
<P>Randomisation: Treatments were numbered by a pharmacist in random order before the start of the study using a random numbers table.<BR/>Blinding: double-blind.<BR/>Number excluded: documented (26%).<BR/>Withdrawals: 8 documented. <BR/>Baseline characteristics: imbalances demonstrated; no adjusted analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Children's Hospital in Brighton, UK. <BR/>Participants: age &gt; 18 mo. with acute asthma requiring admission (after 5 mg nebulised salbutamol and re-assessment in 30 minutes) if study investigator available.<BR/>Asthma definition and severity: "severe". severe asthma requiring admission <BR/>Exclusion criteria: Mild asthma, croup, corticosteroids within the past 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 2 mg/kg oral prednisolone <BR/>Control: identical placebo<BR/>Co-interventions: 5 mg nebulized salbutamol q 1-4 hrs x 3 hrs. Supplemental oxygen was used for nebulisation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: based on history, physical findings, and response to therapy (at 4 hours).<BR/>Pulmonary functions: PEFR and % predicted PEFR<BR/>Adverse effects: tremor, hyperactivity, vomiting, headache.<BR/>Vital signs: pulse rate, saturation, <BR/>Symptoms: scale from 0-6. <BR/>Lab: not reported.<BR/>Timing of assessment: 0, q 30 minutes, 4 hours.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Author correspondence successful, but unable to provide data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Connett-1994b">
<CHAR_METHODS>
<P>Randomisation: Treatments were numbered by a pharmacist in random order before the start of the study using a random numbers table.<BR/>Blinding: double-blind.<BR/>Number excluded: documented (26%).<BR/>Withdrawals: 8 documented. <BR/>Baseline characteristics: imbalances demonstrated; no adjusted analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Children's Hospital in Brighton, UK. <BR/>Participants: age &gt; 18 mo., with acute asthma requiring admission (after 5 mg nebulised salbutamol and re-assessment in 30 minutes) if study investigator available.<BR/>Asthma definition and severity: "severe". severe asthma requiring admission <BR/>Exclusion criteria: Mild asthma, croup, corticosteroids within the past 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 2 mg/kg soluble prednisolone (oral agent).<BR/>Control: identical oral placebo.<BR/>Co-interventions: After corticosteroid treatment children were treated with 0.15 mg/kg q 30 min x 3 hrs. Supplemental oxygen was used for nebulisation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: based on history, physical findings, and response to therapy (at 4 hours).<BR/>Pulmonary functions: PEFR and % predicted PEFR<BR/>Adverse effects: tremor, hyperactivity, vomiting, headache.<BR/>Vital signs: pulse rate, saturation, <BR/>Symptoms: scale from 0-6. <BR/>Lab: not reported.<BR/>Timing of assessment: 0, q 30 minutes, 4 hours.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lin-1997">
<CHAR_METHODS>
<P>Randomisation: non-study nurse allocated treatment and provided a filled syringe with either saline or active drug. <BR/>Blinding: "double blinded" - similar appearing medication<BR/>Number excluded: convenience sample of 48 patients, exclusions not reported.<BR/>Withdrawals: 3 (repeat entry)<BR/>Baseline characteristics: no imbalances demonstrated; adjusted analyses performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: New York City hospital ED.<BR/>Participants: adults (&gt; 17 yrs), acute asthma (clinical definition: prior diagnosis of asthma and history of improvement with B-agonists). <BR/>Asthma definition and severity: &lt; 200 L/min PEFR <BR/>Exclusion criteria: age &lt; 18, smoking history of &gt; 20 pack years, pregnancy, received nebulised B-agonists from EM personnel prior to the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: 125 mg methylprednisolone (MP) IV<BR/>Conrol: equivolume IV saline <BR/>Co-interventions in both groups: 2.5 mg albuterol with 0.5 mg ipratropium bromide, then q 20 min X 2 (2.5 mg albuterol), and 30 minutes later 2.5 mg albuterol. Supplemental oxygen was used for nebulisation and between treatments.<BR/>Cross-over: treating physicians were permitted to administer 125 mg of MP if response was deemed inadequate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: accessory muscle use, RR &gt; 24/min, ABG PCO2 &gt; 44 mm Hg or PO2 &lt; 70 mm Hg, pneumonia or T &gt; 38.8 C, or failure to improve after 5-6 hours AND associated fatigue and shortness of breath. <BR/>Pulmonary functions: PEFR and % predicted PEFR<BR/>Adverse effects: agitation, tremor.<BR/>Vital signs: pulse rate.<BR/>Symptoms: none reported.<BR/>Lab: not reported.<BR/>Timing of assessment: 0, 20, 40, 60 minutes</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Author correspondence pending.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lin-1999">
<CHAR_METHODS>
<P>Randomisation: sealed opaque envelopes, non-study physician read allocation, and filled syringe with either saline or active drug. <BR/>Blinding: "double blinded"<BR/>Number excluded: convenience sample of 60 patients, exclusions not reported.<BR/>Withdrawals: 4 (repeat entry)<BR/>Baseline characteristics: imbalance demonstrated. No adjusted analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: New York City hospital ED.<BR/>Participants: adults (&gt; 18 yrs), acute asthma (clinical definition: history, response to B-agonists, past prescription for B-agonists). <BR/>Asthma definition and severity: &lt; 50% predicted PEFR after single nebulised 2.5 mg salbutamol. <BR/>Exclusion criteria: age &lt; 18, smoking history of &gt; 20 pack years, pregnancy, inability to perform PEFR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: 125 mg methylprednisolone (MP) IV . <BR/>Conrol: equivolume IV saline .<BR/>Co-interventions in both groups: 2.5 mg albuterol with 0.5 mg ipratropium bromide, then q 20 min X 3 - 2.5 mg albuterol, and 30 minutes later 2.5 mg albuterol. Supplemental oxygen was used for nebulisation and between treatments.<BR/>Cross-over: treating physicians were permitted to administer 125 mg of MP if response was deemed inadequate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: accessory muscle use, RR &gt; 24/min, ABG PCO2 &gt; 44 mm Hg or PO2 &lt; 70 mm Hg, pneumonia or T &gt; 38.8 degrees C, or failure to improve after 5-6 hours AND associated fatigue and shortness of breath. <BR/>Pulmonary functions: PEFR and % predicted PEFR<BR/>Adverse effects: tremor.<BR/>Vital signs: pulse rate.<BR/>Symptoms:"symptomatic complaints"<BR/>Lab: not reported<BR/>Timing of assessment: 0, 20, 40, 60, 90 minutes</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Author correspondence pending.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Littenberg-1986">
<CHAR_METHODS>
<P>Randomisation: The vials were filled by a pharmacist at a remote site according to random sequence.<BR/>Blinding: "double blinded" - similar appearance of treatment and placebo.<BR/>Number excluded: not reported.<BR/>Withdrawals: not reported.<BR/>Baseline characteristics: no imbalances demonstrated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Adult ED in Hartford, USA.<BR/>Participants: Patients =&gt;18 ys, acute exacerbation of asthma, no underlying medical conditions <BR/>Asthma definition and severity: hetereogenous population.<BR/>Exclusion criteria: Patients using steroid medication within 2 weeks of presentation, ED MD diagnosis of chronic bronchitis or emphysema.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: within 30 minutes of arrival, 125 mg of IV methylprednisolone (MP) diluted to 3 ml with saline.<BR/>Control: Identical 3 ml of saline IV. <BR/>Co-interventions: Each patient was treated as indicated, with subcutaneous epinephrine or terbutaline, oxygen, metaproterenol sulfate (administered as an aerosol), and intravenous aminophylline.<BR/>Cross-over: not permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: no criteria; physician determined.<BR/>Symptom scores: mild, moderate, severe.<BR/>PEFRs: FVC, FEV-1.<BR/>Adverse effects: "toxicity" but not defined.<BR/>Timing: assessment made at 4 hours. <BR/>Follow-up: relapse at 1 week.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>No response from the author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McFadden-1976">
<CHAR_METHODS>
<P>Randomisation: Not reported.<BR/>Blinding: "double blinded" - no report of method.<BR/>Number excluded: not reported.<BR/>Withdrawals: not reported.<BR/>Baseline characteristics: description of patients limited; no adjusted analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: EDs in Boston and Galveston, USA.<BR/>Participants: adults (16-44 yr), acute allergic or intrinsic asthma .<BR/>Asthma definition and severity: severe (% predicted FEV-1 &lt; 30.1 %).<BR/>Exclusion criteria: use of corticosteroids within a month of ED presentation; no others reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 0.25, 0.5, or 1.0 gm of hydrocortisone upon completion of interview (? time).<BR/>Control: similar appearing saline solution.<BR/>Co-interventions: 30 minutes after corticosteroid treatment, nebulised isopreterenol (0.5 ml) by positive pressure breathing. This was "repeated" variable times over the course of the care in the ED. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: not reported. <BR/>Pulmonary functions: FEV-1 and % predicted FEV-1; airway resistance and conductance.<BR/>Adverse effects: not reported.<BR/>Vital signs: not reported.<BR/>Symptoms: subjective dyspnea rating.<BR/>Lab: not reported<BR/>Timing of assessment: 0, 30, 60 minutes; minimum of 6 hours. </P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>No data could be extracted for use in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rodrigo-1994">
<CHAR_METHODS>
<P>Randomisation: Random number allocation was used to randomise the patients.<BR/>Blinding: "double blinded" - similar appearing agents.<BR/>Number excluded: not reported.<BR/>Withdrawals: not reported.<BR/>Baseline characteristics: no imbalances demonstrated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Military hospital in Montevideo, Uruguay.<BR/>Participants: 98 adults (18 - 50 yrs), with bronchial asthma.<BR/>Asthma definition and severity: PEFR and FEV-1 &lt;50% of predicted value.<BR/>Exclusion criteria: Hx of chronic cough, chronic sputum production; cardiac, hepatic, renal, or other medical disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 500 mg of IV hydrocortisone as 3 ml solution immediately after arrival to the ED.<BR/>Control: placebo of 3 ml of normal saline<BR/>Co-interventions: salbutamol by MDI + spacer , 4 puffs actuated in rapid succession (100 micrograms per actuation), q 10 min. Hospitalization was mandatory if treatment time was greater than 6 hours. Prednisone 40 mg x 5 days tapered dose was prescribed to those patients discharged from the ED.<BR/>Cross-over: not permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: discharged after 6 hours if met the following criteria: free of dyspnea, no accessory muscles use at rest, and no wheezing.<BR/>Pulmonary functions: PEF, FEV-1, FVC (absolute and % predicted).<BR/>Adverse effects: tremor, headache, anxiety, palpitations, and nausea.<BR/>Vital signs: . Heart rate, respiratory rate, blood pressure.<BR/>Symptoms: 0-3 scale (mild, moderate, severe); accessory muscle use, dyspnea and wheezing were assessed throughout the patient's stay in the ER. <BR/>Lab: theophylline levels.<BR/>Timing of assessment: q 30 minutes.<BR/>Follow-up: phone call to discharged patients to determine relapse rates. A retrospective chart review was also done in order to identify any patients returning to the ED.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Authors corresponded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scarfone-1993">
<CHAR_METHODS>
<P>Randomisation: Randomisation of drug or placebo preparation was done by ED physicians who were not involved with the study. Randomisation was accomplished using a random numbers table.<BR/>Blinding: "double blinded"<BR/>Number excluded: not stated.<BR/>Withdrawals: 6 (5 steroids; 1 placebo).<BR/>Baseline characteristics: no imbalances demonstrated. No adjusted analyses.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Children's Hospital in Philadelphia, USA. <BR/>Participants: 75 children (1-17 yrs), exacerbation of asthma with at least one prior episode of wheezing, and initial PIS &gt; 8.<BR/>Asthma definition and severity: "moderate" as described by author. Subgroup: PIS &gt; 10 vs PIS &lt; 10<BR/>Exclusion criteria: use of inhaled or systemic steroids within the previous 72 hours, other serious medical condition, pneumonia, vomited study drug within 15 minutes of administration <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 2 mg/kg of oral prednisone after first albuterol treatment.<BR/>Placebo: similar appearing placebo capsule. <BR/>If unable to swallow, capsule was mixed with 5 ml of juice; patients who vomited within 15 minutes, were given a repeat dose.<BR/>Co-intervention: Patients in each group were then treated with an identical regimen of frequent aerosolized albuterol, for a maximum of 4 hours.<BR/>Cross-over: not permitted. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: Determined at 4 hours by blinded physician. Based on oxygen saturation of &lt; 92%, poor aeration by auscultation, or continued significant retractions. <BR/>Pulmonary functions: PEFR and % predicted PEFR. Since 2/3 of patients &lt; 6 yrs, PFT collection abandoned early in the study. Admission to hospital at 2 hours was provided by the author.<BR/>Adverse effects: not reported.<BR/>Vital signs: respiratory rate, oxygen saturation, respiratory rate. <BR/>Symptoms: pulmonary index score.<BR/>Lab: not reported<BR/>Timing of assessment: 2 and 4 hours.<BR/>Follow-up: relapse rates for those discharged from ED</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Dr. Scarfone responded to correspondence and provided additional information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schneider-1988">
<CHAR_METHODS>
<P>Randomisation: Patients were randomised using computer-generated random numbers and randomised separately according to chronic steroid dependency.<BR/>Blinding: double blinded - similar appearing <BR/>Number excluded: <BR/>Withdrawals: 2 (1 pneumonia: MP; 1 tachycardia: placebo)<BR/>Baseline characteristics: limited reporting; no adjusted analyses.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Montefiore Hospital in Pittsburgh, USA.<BR/>Participants: 56 adults, Dx of asthma, acute bronchospasm and dyspnea, <BR/>Asthma definition and severity: FEV-1 &lt; 70% predicted. No severity subgroups. <BR/>Exclusion criteria: TB, pregnancy, diabetes mellitus, pneumonia or congestive heart failure <BR/>Subgroups: Patients were considered non-steroid dependent if they had used no steroid treatment within the past 14 days.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: methylprednisolone (MP: 30 mg/kg) infused over 30 min.<BR/>Control: saline placebo <BR/>Co-interventions: Treatment begun with epinephrine, 0.3 ml sub-Q in patients &lt; 35 yrs or isoetharine 0.5 ml (updraft nebulization, followed by the inhalation of albuterol). If subsequent FEV-1 showed improvement &gt; 20%, the patient received beta-agonist q 30 min until improvement ceased, or discharge criteria met. Patients failing to improve received IV aminophylline in addition to the beta-agonists.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: hospitalized if failed to improve during initial or any subsequent 60 minute period of combined aminophylline maintenance infusion and beta-agonist therapy. Discharged if clinical signs and symptoms of bronchospasm had cleared and the FEV-1 =&gt;70% of predicted or previous best.<BR/>Pulmonary functions: FEV-1 and % predicted FEV-1.<BR/>Adverse effects: none.<BR/>Vital signs: none.<BR/>Symptoms: none.<BR/>Lab: not reported.<BR/>Timing of assessment: entry, q 30 minutes<BR/>Follow-up: Patients were considered treatment failures if they required hospitalization within 7 days after being successfully treated. Relapses were determined by chart audits as all patients were likely to return to the same hospital.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Dr. Schneider responded to correspondence, and was able to provide additional information including the data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 15:04:33 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Stein-1990">
<CHAR_METHODS>
<P>Randomisation: Random numbers table. Drug prepared by ED physician not involved in recruitment. <BR/>Blinding: double blinded - similar appearing <BR/>Number excluded: not reported.<BR/>Withdrawals: 13 (%) of 104 visits. Described, but not reported in groups allocated. <BR/>Baseline characteristics: no imbalances demonstrated. No adjusted analyses. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: ED, Presbyterian Hospital, NY, USA.<BR/>Participants: 81 adults (91 visits) (18-45 yrs), acute bronchial asthma. Corticosteroid use permitted.<BR/>Asthma definition and severity: not reported.<BR/>Exclusion criteria: serious underlying medical illness (sickle cell, HIV, cancer, heart disease), pneumonia, pregnancy, or temperature &gt;38.3 C. Patients could be entered &gt;1.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: 125 mg IV methylprednisolone (MP; 3 ml) 30 minutes after initial treatment.<BR/>Control: IV normal saline <BR/>Co-interventions: 3 aerosolized metaproterenol (q 30 min X 2 hrs) and oral theophylline therapy.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-23 15:04:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Admission: At discretion of treating physician, no specific criteria: relief of wheezing, clear chest examinations, or minimal wheezing. Six hours after study entry, remaining patients were treated with 40mg IV MP. Hospitalization was mandatory if total treatment time was greater than 12 hours.<BR/>Pulmonary functions: PEFR.<BR/>Adverse effects: not reported.<BR/>Vital signs: temperature, pulse rate, respiratory rate, and blood pressure.<BR/>Symptoms: 0-3 (none, mild, moderate, severe).<BR/>Lab: theophylline levels, complete lymphocyte level, electrolytes, .<BR/>Timing of assessment: entry, 30 minutes, and 2, 4, 6 hours.<BR/>Duration in the ED: measured.<BR/>Relapse: 2 and 7 day follow-up of discharged patients.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Author provided 6 hour admission data for this analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-23 15:04:31 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Storr-1987">
<CHAR_METHODS>
<P>Randomisation: Hospital pharmacy using random numbers table<BR/>Blinding: double blinded - similar appearing and tasting (grapefruit-flavoured mixture) Number excluded: well described.<BR/>Withdrawals: described, and based on allocation (prednisone = 2; placebo = 2). <BR/>Baseline characteristics: no imbalances demonstrated. No adjusted analyses. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-23 15:04:31 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Location: Children's Hospital, Brighton, UK.<BR/>Participants: 140 children, moderate-severe acute asthma. Information on the subgroup of patients receiving inhaled steroids at the study enrolment was available.<BR/>Asthma definition and severity: moderate-severe<BR/>Exclusion criteria: croup, pneumonia, pertussis, congenital heart disease, mental retardation. Any child receiving a steroid within the previous 48 hours was excluded, as well as any child vomiting the study medication within 1 hour of ingestion.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: Children &lt; 5 given 30 mg of oral prednisone, =&gt;5 received 60 mg . <BR/>Control: identical placebo.<BR/>Co-interventions: nebulised salbutamol 5 mg in 2 ml saline on admission and three or more times daily when needed. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: At six hours, by treating MD, no specific criteria.<BR/>Pulmonary functions: PEFR and % predicted.<BR/>Adverse effects: none<BR/>Vital signs: none.<BR/>Symptoms: 0 -10 scale (0 = good, 10 = poor).<BR/>Lab: not reported<BR/>Timing of assessment: entry, 30 minutes, and 4 hours.<BR/>Administrative data: times of admission, length of hospital stay.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Dr. Storr responded to correspondence and provided additional information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tal-1990">
<CHAR_METHODS>
<P>Randomisation: Central pharmacy prepared solution using a random numbers table.<BR/>Blinding: double blinded - similar appearance - all delivered by IM injection.<BR/>Number excluded: not reported.<BR/>Withdrawals: 2 (described).<BR/>Baseline characteristics: minimal imbalance demonstrated. No adjusted analyses. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: ED at Children's Hospital in Beer Sheva, Isreal.<BR/>Participants: 75 children ( 6-60 mo), acute asthma. at least 3 prior episodes of wheezing. Only the subgroup of patients between 25-54 months were used in this analysis<BR/>Asthma definition and severity: moderate (PIS: 6-8) and severe (PIS: 9-11).<BR/>Exclusion criteria: pneumonia, cystic fibrosis, foreign body aspiration, broncho-pulmonary dysplasia, or other respiratory illness. Corticosteroids within 1 month prior to presentation. PIS &lt; 5 and &gt; 11.</P>
<P/>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: single dose of IM methylprednisolone (MP: 4mg/kg).<BR/>Control: single dose of IM saline placebo.<BR/>Co-interventions: salbutamol nebulisation at presentation and q 30 min following intervention. Oxygen was used to drive delivery.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: decision made at 3 hours based on clinical criteria at the discretion of the senior resident. <BR/>Pulmonary functions: PFTs were not recorded due to the young age of the sample. <BR/>Adverse effects: not recorded.<BR/>Vital signs: no.<BR/>Symptoms: 0 - 12. Pulmonary index score (PIS). <BR/>Lab: not routine (at discretion of MD).<BR/>Timing of assessment: entry, 30 minutes and 3 hours. All made by same physician. <BR/>Relapse: Telephone contact at 5 days to determine relapse.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Dr. Tal responded and provided supplemental information in addition to data extraction verification. A matched pairs design (matched on the basis of age group and disease severity) was employed and the analyses in the paper are more robust than the ones employed for this meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolfson-1994">
<CHAR_METHODS>
<P>Randomisation: A predetermined random sequence established by the pharmacist to allocated treatment; vials were prepared daily by a pharmacist.<BR/>Blinding: double blinded - similar appearance <BR/>Number excluded: not reported.<BR/>Withdrawals: none reported.<BR/>Baseline characteristics: no imbalances demonstrated. No adjusted analyses.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: ED Children's Hospital, Chicago, USA. <BR/>Participants: 88 children, (4 - 18 yrs), Dx of asthma, acute asthma, without other serious medical problems <BR/>Exclusion criteria: First-time episodes of wheezing, fever &gt; 38.5 C, patients who had taken systemic corticosteroids within 2 weeks of presentation. <BR/>Asthma definition and severity: none.<BR/>No child enrolled &gt; once</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: Maximum 125 mg IV methylprednisolone (MP: 2 mg/kg) within 45 minutes of arrival.<BR/>Control: equivalent volume (2 ml) saline placebo <BR/>Co-interventions: usual ED management of their acute exacerbation including subcutaneous epinephrine, IV access, oxygen, and B-agonists (at the discretion of the treating MD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admission: at 3 hours, clinical decision (lack of resolution of wheezing) made by non-treating MD.<BR/>Pulmonary functions: PEFR (discontinued at some time during the study due to technical difficulties).<BR/>Adverse effects: none.<BR/>Vital signs: "recorded".<BR/>Symptoms: 0 - 10 (Woods-Downes Asthma Score).<BR/>Lab: not reported<BR/>Timing of assessment: entry and discharge or admission (mean of 2.8 hours - CS group; 3.0 hours - placebo group).<BR/>Administrative: time to disposition, length of stay.<BR/>Follow-up: 24 hours for discharged patients.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score:<BR/>Dr. Wolfson responded to correspondence, but was unable to provide additional information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-23 15:04:03 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-07-23 15:04:03 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Afilalo-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 15:04:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>RCT of inhaled corticosteroids vs standard care in ED.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arnaud-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of in-patients receiving corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barnett-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>IV vs oral corticosteroid in ED prevention of admission. No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deshpande-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Home-based, out-patient treatment with corticosteroids (correspondence with authors).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fanta-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>In-patient treatment protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-23 15:03:58 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Guttman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-23 15:03:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>RCT of inhaled corticosteroids vs standard care in ED. No placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klig-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>IV vs oral corticosteroids for out-patient care. No placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morray-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ogirala-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were experiencing chronic asthma, as opposed to an acute exacerbation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pansegrouw-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of inhaled corticosteroids vs standard care in ED. No placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodrigo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of inhaled corticosteroids vs standard care in ED. No placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scarfone-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT comparing two different delivery systems (oral vs nebulization), doses, and therapeutic agents (prednisone vs dexamethasone) for the treatment of acute asthma. Admission rates were reported, but no placebo arm was documented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuckerman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>IV vs oral RCT in out-patient setting. No placebo arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shapiro-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of oral steroids as out-patients after discharge from the acute care setting.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sung-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of inhaled corticosteroids vs standard care in ED.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volovitz-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of inhaled corticosteroids vs standard care in ED.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-23 15:07:02 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-23 15:07:02 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:07:02 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Connett-1994a">
<DESCRIPTION>
<P>Treatments were numbered by a pharmacist in random order before the start of the study using a random numbers table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:06:50 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Connett-1994b">
<DESCRIPTION>
<P>Treatments were numbered by a pharmacist in random order before the start of the study using a random numbers table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:06:42 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lin-1997">
<DESCRIPTION>
<P>Non-study nurse allocated treatment and provided a filled syringe with either saline or active drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:06:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lin-1999">
<DESCRIPTION>
<P>Sealed opaque envelopes, non-study physician read allocation, and filled syringe with either saline or active drug.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:06:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Littenberg-1986">
<DESCRIPTION>
<P>The vials were filled by a pharmacist at a remote site according to random sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:06:02 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1976">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:05:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rodrigo-1994">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:05:44 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Scarfone-1993">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:05:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Schneider-1988">
<DESCRIPTION>
<P>Patients were randomised using computer-generated random numbers and randomised separately according to chronic steroid dependency.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:05:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Stein-1990">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:04:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Storr-1987">
<DESCRIPTION>
<P>Hospital pharmacy using random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tal-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 15:04:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wolfson-1994">
<DESCRIPTION>
<P>A predetermined random sequence established by the pharmacist to allocated treatment; vials were prepared daily by a pharmacist.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-23 15:37:06 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-23 15:37:06 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Any steroid (po, IM, IV, inhaled) vs placebo</NAME>
<DICH_OUTCOME CHI2="21.270428283824657" CI_END="0.8057196389073471" CI_START="0.3128453624947027" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5020614031202458" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="209" I2="48.285009341513465" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.09381605057322172" LOG_CI_START="-0.5046702784613938" LOG_EFFECT_SIZE="-0.29924316451730776" METHOD="MH" MODIFIED="2008-07-23 15:37:06 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.030675178793878932" P_Q="0.0" P_Z="0.004302929984585178" Q="0.0" RANDOM="YES" SCALE="113.90721033153504" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3218916099635692" TOTALS="YES" TOTAL_1="426" TOTAL_2="418" WEIGHT="100.00000000000001" Z="2.855055566001648">
<NAME>Admitted to hospital (all times)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="86" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="6.032632011040121"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="87" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="5.9901747381984"/>
<DICH_DATA CI_END="5.654411957739128" CI_START="0.3913150061469368" EFFECT_SIZE="1.4875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7523874462573839" LOG_CI_START="-0.40747349745620953" LOG_EFFECT_SIZE="0.1724569744005872" ORDER="88" O_E="0.0" SE="0.6813080597416323" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.4641806722689076" WEIGHT="7.409488734250426"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="89" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="8.96168232377014"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="90" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="10.774271178064527"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="91" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="7.130387641459284"/>
<DICH_DATA CI_END="1.194211140968347" CI_START="0.17962923648754467" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.07708111846065528" LOG_CI_START="-0.7456229760659759" LOG_EFFECT_SIZE="-0.33427092880266035" ORDER="92" O_E="0.0" SE="0.48326045757589076" STUDY_ID="STD-Scarfone-1993" TOTAL_1="36" TOTAL_2="39" VAR="0.23354066985645933" WEIGHT="10.486235552235607"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="93" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="8.119362842494409"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="94" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="11.692427178785856"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="95" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="6.427667960226818"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="96" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="5.76715015207582"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="97" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="11.208519687398608"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9813725684375411" CI_END="4.665599666996281" CI_START="0.4106828499854489" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3842260538413491" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.6689074713044161" LOG_CI_START="-0.38649343279815795" LOG_EFFECT_SIZE="0.14120701925312898" METHOD="MH" NO="2" P_CHI2="0.32186039792824717" P_Q="0.0" P_Z="0.5999548240104743" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="62" WEIGHT="100.00000000000001" Z="0.5244654823101964">
<NAME>Admitted to hospital (1-2 hours)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="98" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="75.22521382020368"/>
<DICH_DATA CI_END="5.456079539658852" CI_START="0.04135295285928098" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7368806929136607" LOG_CI_START="-1.3834934736639275" LOG_EFFECT_SIZE="-0.3233063903751334" ORDER="99" O_E="0.0" SE="1.2455182814690775" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="1.5513157894736842" WEIGHT="24.774786179796333"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.732774678988072" CI_END="0.9078527971961888" CI_START="0.239570055997577" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.46636289031380684" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="88" I2="48.627188392695274" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.04198456397672817" LOG_CI_START="-0.6205674656137177" LOG_EFFECT_SIZE="-0.33127601479522295" METHOD="MH" NO="3" P_CHI2="0.08317098546638424" P_Q="0.0" P_Z="0.024805937524085258" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3219903070723211" TOTALS="YES" TOTAL_1="185" TOTAL_2="181" WEIGHT="100.0" Z="2.244411496100407">
<NAME>Admitted to hospital (3-4 hours)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="100" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="11.962394205022216"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="101" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="11.878212195447748"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="102" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="21.36310069129025"/>
<DICH_DATA CI_END="1.0257519556585486" CI_START="0.1601149539523626" EFFECT_SIZE="0.4052631578947368" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.011042353648608057" LOG_CI_START="-0.7955681052093022" LOG_EFFECT_SIZE="-0.39226287578034713" ORDER="103" O_E="0.0" SE="0.4738069763193027" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22449305080884027" WEIGHT="21.13632379823861"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="104" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="11.436008986402749"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="105" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="22.223960123598427"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.770443849885122" CI_END="0.6394648572544339" CI_START="0.14828525966499045" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.307933779252309" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="166" I2="66.23607125019116" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.19418331783091264" LOG_CI_START="-0.8289020179825699" LOG_EFFECT_SIZE="-0.5115426679067412" METHOD="MH" NO="4" P_CHI2="0.00683224025728113" P_Q="0.0" P_Z="0.0015819681586954932" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6281827057136582" TOTALS="YES" TOTAL_1="308" TOTAL_2="298" WEIGHT="99.99999999999999" Z="3.1592111762681254">
<NAME>Admitted to hospital (5-6 hours)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.25840185033731883" CI_START="0.026215118485139577" EFFECT_SIZE="0.0823045267489712" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" LOG_CI_END="-0.5877043808146853" LOG_CI_START="-1.5814481750539764" LOG_EFFECT_SIZE="-1.084576277934331" ORDER="106" O_E="0.0" SE="0.5837300238472755" STUDY_ID="STD-Connett-1994a" TOTAL_1="37" TOTAL_2="33" VAR="0.34074074074074073" WEIGHT="14.346578077523443"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="107" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="14.537279610910678"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="108" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="16.414160006263216"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="109" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="12.376758379372841"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="110" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="13.579747962314999"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="111" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="17.2803392267515"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="112" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="11.46513673686331"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Route of administration (Admission)</NAME>
<DICH_OUTCOME CHI2="11.985406618524074" CI_END="1.2084801104921084" CI_START="0.38588101327162244" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6828832473822279" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="93" I2="49.939120207013374" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.08223950706091596" LOG_CI_START="-0.4135465897473975" LOG_EFFECT_SIZE="-0.16565354134324073" METHOD="MH" NO="1" P_CHI2="0.06229525620522036" P_Q="0.0" P_Z="0.19028444341738593" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.28853468578568264" TOTALS="YES" TOTAL_1="263" TOTAL_2="266" WEIGHT="100.00000000000001" Z="1.3097381190574142">
<NAME>IV vs placebo</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>IV steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="113" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="10.60898916341038"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="114" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="13.755773988990896"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="115" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="16.720984802467907"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="116" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="10.825143435211412"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="117" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="12.39979848849202"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="118" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="18.248170762521056"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="119" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="17.44113935890634"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.074592224876005" CI_END="0.5341953574544832" CI_START="0.11201266326635158" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.24461529938455878" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="111" I2="26.373000427268675" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.2722998906326189" LOG_CI_START="-0.9507328766528742" LOG_EFFECT_SIZE="-0.6115163836427466" METHOD="MH" NO="2" P_CHI2="0.25352145036784457" P_Q="0.0" P_Z="4.1042271117999095E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1710787941246321" TOTALS="YES" TOTAL_1="151" TOTAL_2="140" WEIGHT="99.99999999999999" Z="3.533289543973259">
<NAME>Oral vs Placebo</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Oral steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="120" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="19.49432359486253"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="121" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="19.33193672344648"/>
<DICH_DATA CI_END="1.0257519556585486" CI_START="0.1601149539523626" EFFECT_SIZE="0.4052631578947368" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.011042353648608057" LOG_CI_START="-0.7955681052093022" LOG_EFFECT_SIZE="-0.39226287578034713" ORDER="122" O_E="0.0" SE="0.4738069763193027" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22449305080884027" WEIGHT="40.147983988669516"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="123" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="21.025755693021477"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Chronic corticosteroid use prior to ED</NAME>
<DICH_OUTCOME CHI2="15.205497591389147" CI_END="0.6973459868219742" CI_START="0.19132867162461253" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3652701484126548" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="161" I2="53.964018882459385" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.1565516940888098" LOG_CI_START="-0.7182199437452301" LOG_EFFECT_SIZE="-0.43738581891702" METHOD="MH" NO="1" P_CHI2="0.033453635635892986" P_Q="0.0" P_Z="0.0022690526711873875" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4457304980041777" TOTALS="YES" TOTAL_1="277" TOTAL_2="268" WEIGHT="100.0" Z="3.0525508712672087">
<NAME>Excluded</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="124" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="9.992620160228851"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="125" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="9.930237976032558"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="126" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="16.382895652895158"/>
<DICH_DATA CI_END="1.0257519556585486" CI_START="0.1601149539523626" EFFECT_SIZE="0.4052631578947368" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.011042353648608057" LOG_CI_START="-0.7955681052093022" LOG_EFFECT_SIZE="-0.39226287578034713" ORDER="127" O_E="0.0" SE="0.4738069763193027" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22449305080884027" WEIGHT="16.241093626708082"/>
<DICH_DATA CI_END="1.290374636867224" CI_START="0.06130123782659199" EFFECT_SIZE="0.28125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.11071581813101222" LOG_CI_START="-1.2125307558921745" LOG_EFFECT_SIZE="-0.5509074688805811" ORDER="128" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Schneider-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.6041666666666666" WEIGHT="10.367837701999521"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="129" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="10.5682938518187"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="130" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="9.600901793062581"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="131" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="16.916119237254534"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5337571479251184" CI_END="1.3965312741264757" CI_START="0.48052791247326015" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8191900010739985" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.1450506658003414" LOG_CI_START="-0.31828138035540743" LOG_EFFECT_SIZE="-0.08661535727753297" METHOD="MH" NO="2" P_CHI2="0.4727641459221854" P_Q="0.0" P_Z="0.46368537968986345" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="154" TOTAL_2="151" WEIGHT="99.99999999999999" Z="0.7327918808144266">
<NAME>Mixed population</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="132" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="14.498169911091944"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="133" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="22.58114278740126"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="134" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="14.965767592262367"/>
<DICH_DATA CI_END="2.236723317691031" CI_START="0.027942660366468017" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.349612265262609" LOG_CI_START="-1.5537322479185336" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="135" O_E="0.0" SE="1.118033988749895" STUDY_ID="STD-Schneider-1988" TOTAL_1="8" TOTAL_2="7" VAR="1.25" WEIGHT="5.925839289057421"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="136" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="42.029080420187"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Severity at Admission</NAME>
<DICH_OUTCOME CHI2="11.246079369054517" CI_END="0.5877587562291233" CI_START="0.21080310581781145" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3519962660096171" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="180" I2="37.75608574076331" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.23080089218402833" LOG_CI_START="-0.676122994837096" LOG_EFFECT_SIZE="-0.45346194351056224" METHOD="MH" NO="1" P_CHI2="0.12823959226947268" P_Q="0.0" P_Z="6.563493921362708E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.19990954619065626" TOTALS="YES" TOTAL_1="300" TOTAL_2="289" WEIGHT="99.99999999999999" Z="3.991578555590545">
<NAME>High Admit Rate ( Placebo Admission Rate &gt; 40% )</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="137" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="8.112206265594528"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="138" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="8.046923037596292"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="139" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="12.96102242268368"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="140" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="16.346430945277593"/>
<DICH_DATA CI_END="1.0257519556585486" CI_START="0.1601149539523626" EFFECT_SIZE="0.4052631578947368" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.011042353648608057" LOG_CI_START="-0.7955681052093022" LOG_EFFECT_SIZE="-0.39226287578034713" ORDER="141" O_E="0.0" SE="0.4738069763193027" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22449305080884027" WEIGHT="16.12299328976352"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="142" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="11.493202763828867"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="143" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="18.19116789312693"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="144" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="8.726053382128585"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4146183905005203" CI_END="2.2197898675270347" CI_START="0.6616668960625265" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.21192469714816" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.3463118646791095" LOG_CI_START="-0.17936059305326585" LOG_EFFECT_SIZE="0.08347563581292176" METHOD="MH" NO="2" P_CHI2="0.7021119404054854" P_Q="0.0" P_Z="0.5336289352748584" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="130" WEIGHT="99.99999999999999" Z="0.6224759824232738">
<NAME>Low Admit Rate (Placebo Admission Rate &lt; 40%)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="145" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="18.662033005086542"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="146" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="19.263924375695204"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="147" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="13.857842831527773"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="148" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="48.21619978769048"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Quality Assessment (Admission)</NAME>
<DICH_OUTCOME CHI2="10.318057421866268" CI_END="0.9049749139784168" CI_START="0.2126491439205471" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.43868227765329326" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="81" I2="51.54126600028525" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.043363459327113406" LOG_CI_START="-0.6723363613220756" LOG_EFFECT_SIZE="-0.3578499103245945" METHOD="MH" NO="1" P_CHI2="0.06670886263577569" P_Q="0.0" P_Z="0.025733059860983946" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.40519306635008695" TOTALS="YES" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="2.2302167037164695">
<NAME>High quality (Cochrane)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="149" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="13.015279949499893"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="150" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="12.930907638800253"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="151" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="21.879355689510724"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="152" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="17.048950969606896"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="153" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="12.486152190998995"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="154" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="22.63935356158325"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.606622298314054" CI_END="1.1806977379252388" CI_START="0.28157417022670567" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5765882290203708" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="127" I2="56.921144916326895" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.07213873118458008" LOG_CI_START="-0.5504071870388576" LOG_EFFECT_SIZE="-0.23913422792713876" METHOD="MH" NO="2" P_CHI2="0.04059420940588199" P_Q="0.0" P_Z="0.1321353100939419" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4429947995964452" TOTALS="YES" TOTAL_1="255" TOTAL_2="250" WEIGHT="100.0" Z="1.5057346309345345">
<NAME>Low quality (Cochrane)</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="155" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="14.01882845742543"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="156" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="17.344008039794982"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="157" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="14.257419823973445"/>
<DICH_DATA CI_END="1.194211140968347" CI_START="0.17962923648754467" EFFECT_SIZE="0.4631578947368421" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.07708111846065528" LOG_CI_START="-0.7456229760659759" LOG_EFFECT_SIZE="-0.33427092880266035" ORDER="158" O_E="0.0" SE="0.48326045757589076" STUDY_ID="STD-Scarfone-1993" TOTAL_1="36" TOTAL_2="39" VAR="0.23354066985645933" WEIGHT="19.766392425302072"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="159" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="21.59539047180063"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="160" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="13.017960781703437"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Population</NAME>
<DICH_OUTCOME CHI2="8.783547702077332" CI_END="1.0656501496401858" CI_START="0.3207340121930388" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5846282990825957" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="78" I2="43.07539311458982" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.027614650264210068" LOG_CI_START="-0.49385498293243923" LOG_EFFECT_SIZE="-0.2331201663341146" METHOD="MH" NO="1" P_CHI2="0.11801556321969264" P_Q="0.0" P_Z="0.07970805831804725" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23754171098973734" TOTALS="YES" TOTAL_1="221" TOTAL_2="220" WEIGHT="100.0" Z="1.7523825012934127">
<NAME>Asthmatic Adults Only</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.991232196994398" CI_START="0.4850286497691562" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.902613749914224" LOG_CI_START="-0.31423260764687255" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="161" O_E="0.0" SE="0.7147815739180036" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.5109126984126984" WEIGHT="12.536257353706656"/>
<DICH_DATA CI_END="1.5236403101981497" CI_START="0.1613798494865551" EFFECT_SIZE="0.49586776859504134" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18288245405522421" LOG_CI_START="-0.792150693920837" LOG_EFFECT_SIZE="-0.3046341199328064" ORDER="162" O_E="0.0" SE="0.5727392976130615" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.328030303030303" WEIGHT="16.589960007202528"/>
<DICH_DATA CI_END="0.652354469162534" CI_START="0.10431894510368628" EFFECT_SIZE="0.2608695652173913" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.18551635799580848" LOG_CI_START="-0.9816368132720898" LOG_EFFECT_SIZE="-0.5835765856339492" ORDER="163" O_E="0.0" SE="0.4676450962890987" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" VAR="0.21869193608324042" WEIGHT="20.565815682341835"/>
<DICH_DATA CI_END="3.105796292878936" CI_START="0.19700957411185963" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49217296723933734" LOG_CI_START="-0.7055126678337627" LOG_EFFECT_SIZE="-0.10666985029721263" ORDER="164" O_E="0.0" SE="0.7035264706814485" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.4949494949494949" WEIGHT="12.809460397213096"/>
<DICH_DATA CI_END="0.9743992285472816" CI_START="0.08282810809325566" EFFECT_SIZE="0.2840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.011263068551297663" LOG_CI_START="-1.0818222584049644" LOG_EFFECT_SIZE="-0.546542663478131" ORDER="165" O_E="0.0" SE="0.6288517674735005" STUDY_ID="STD-Schneider-1988" TOTAL_1="27" TOTAL_2="27" VAR="0.39545454545454545" WEIGHT="14.82286348183379"/>
<DICH_DATA CI_END="2.1692999638452175" CI_START="0.41843703859862613" EFFECT_SIZE="0.9527410207939508" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.33631960901534197" LOG_CI_START="-0.3783698801946629" LOG_EFFECT_SIZE="-0.02102513558966047" ORDER="166" O_E="0.0" SE="0.41981214373198483" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" VAR="0.1762422360248447" WEIGHT="22.67564307770209"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.649337334634968" CI_END="0.9382931279637613" CI_START="0.1669388413192464" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.39577464244198585" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="130" I2="63.36818500842101" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.027661464424914867" LOG_CI_START="-0.7774426051537167" LOG_EFFECT_SIZE="-0.4025520347893157" METHOD="MH" NO="2" P_CHI2="0.017997235894304242" P_Q="0.0" P_Z="0.03532781587369614" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7052284882766732" TOTALS="YES" TOTAL_1="210" TOTAL_2="199" WEIGHT="99.99999999999999" Z="2.1045807829294367">
<NAME>Asthmatic Children Only</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>CS therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0878072856046677" CI_START="0.08994018704336201" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31969040876457877" LOG_CI_START="-1.0460462135902302" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="167" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="0.6435897435897435" WEIGHT="14.381056786491754"/>
<DICH_DATA CI_END="0.7729198736736507" CI_START="0.032745848848568355" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="-0.11186552577773107" LOG_CI_START="-1.48484374716613" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="168" O_E="0.0" SE="0.8064942035953515" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.6504329004329004" WEIGHT="14.308463565219897"/>
<DICH_DATA CI_END="1.0257519556585486" CI_START="0.1601149539523626" EFFECT_SIZE="0.4052631578947368" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.011042353648608057" LOG_CI_START="-0.7955681052093022" LOG_EFFECT_SIZE="-0.39226287578034713" ORDER="169" O_E="0.0" SE="0.4738069763193027" STUDY_ID="STD-Scarfone-1993" TOTAL_1="41" TOTAL_2="40" VAR="0.22449305080884027" WEIGHT="20.863700335700425"/>
<DICH_DATA CI_END="0.3647459255843759" CI_START="0.018227813509930992" EFFECT_SIZE="0.08153846153846153" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="-0.43800955071924175" LOG_CI_START="-1.7392654233648912" LOG_EFFECT_SIZE="-1.0886374870420665" ORDER="170" O_E="0.0" SE="0.7643641409125086" STUDY_ID="STD-Storr-1987" TOTAL_1="73" TOTAL_2="67" VAR="0.5842525399129173" WEIGHT="15.042820454954661"/>
<DICH_DATA CI_END="3.518457700835662" CI_START="0.13622160093457059" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5463523342737211" LOG_CI_START="-0.865754020008745" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="171" O_E="0.0" SE="0.8294782625447082" STUDY_ID="STD-Tal-1990" TOTAL_1="17" TOTAL_2="13" VAR="0.688034188034188" WEIGHT="13.92230762865741"/>
<DICH_DATA CI_END="3.3596904617125563" CI_START="0.5878403978832824" EFFECT_SIZE="1.4053333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.5262992663890291" LOG_CI_START="-0.23074057141937365" LOG_EFFECT_SIZE="0.14777934748482774" ORDER="172" O_E="0.0" SE="0.4446889481362904" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" VAR="0.19774826059456038" WEIGHT="21.481651228975835"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>PEFR</NAME>
<CONT_OUTCOME CHI2="8.61927890275007" CI_END="0.8586728766599943" CI_START="-0.4111915156603898" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2237406804998022" ESTIMABLE="YES" I2="65.19430414250989" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="0.034805451453881364" P_Q="1.0" P_Z="0.489777845838991" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2636011962279604" TOTALS="YES" TOTAL_1="69" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="0.6906622129230582">
<NAME>PEFR @ 60 minutes</NAME>
<GROUP_LABEL_1>Systemic CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.403543597367232" CI_START="-0.6494091535539974" EFFECT_SIZE="0.3770672219066173" ESTIMABLE="YES" MEAN_1="-41.0" MEAN_2="-42.7" ORDER="173" SD_1="4.8" SD_2="3.7" SE="0.5237220599752492" STUDY_ID="STD-Connett-1994a" TOTAL_1="7" TOTAL_2="8" WEIGHT="19.510494782446173"/>
<CONT_DATA CI_END="1.0111817933034204" CI_START="-0.9643645720579515" EFFECT_SIZE="0.023408610622734433" ESTIMABLE="YES" MEAN_1="-44.2" MEAN_2="-44.3" ORDER="174" SD_1="4.4" SD_2="3.5" SE="0.5039751701929804" STUDY_ID="STD-Connett-1994b" TOTAL_1="9" TOTAL_2="7" WEIGHT="20.275464907860858"/>
<CONT_DATA CI_END="1.4747609358279572" CI_START="0.24783979260524192" EFFECT_SIZE="0.8613003642165995" ESTIMABLE="YES" MEAN_1="-48.0" MEAN_2="-56.0" ORDER="175" SD_1="9.6" SD_2="8.6" SE="0.31299583892880495" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" WEIGHT="29.024785672565535"/>
<CONT_DATA CI_END="0.19384139688492635" CI_START="-0.8643530247919031" EFFECT_SIZE="-0.3352558139534884" ESTIMABLE="YES" MEAN_1="-234.0" MEAN_2="-200.0" ORDER="176" SD_1="100.0" SD_2="100.0" SE="0.26995251699106004" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" WEIGHT="31.189254637127444"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16498156564578975" CI_START="-0.8946559842504409" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3648372093023256" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.17712956134042251" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.3496460002246726">
<NAME>PEFR @ 120 minutes</NAME>
<GROUP_LABEL_1>Systemic CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.16498156564578975" CI_START="-0.8946559842504409" EFFECT_SIZE="-0.3648372093023256" ESTIMABLE="YES" MEAN_1="-251.0" MEAN_2="-214.0" ORDER="177" SD_1="100.0" SD_2="100.0" SE="0.27032066870986315" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="81.63024036121752" CI_END="0.16534587201221385" CI_START="-15.975620474156464" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.905137301072125" ESTIMABLE="YES" I2="91.42474655345289" I2_Q="0.0" ID="CMP-007.05" NO="5" P_CHI2="5.662137425588298E-15" P_Q="1.0" P_Z="0.05488205824699105" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="98.62158505707148" TOTALS="YES" TOTAL_1="242" TOTAL_2="237" UNITS="" WEIGHT="100.00000000000001" Z="1.9198087736083083">
<NAME>Final PEFR</NAME>
<GROUP_LABEL_1>Systemic CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.338111442008964" CI_START="-12.861888557991024" EFFECT_SIZE="-8.099999999999994" ESTIMABLE="YES" MEAN_1="-52.8" MEAN_2="-44.7" ORDER="178" SD_1="4.6" SD_2="4.8" SE="2.429579622662559" STUDY_ID="STD-Connett-1994a" TOTAL_1="7" TOTAL_2="8" WEIGHT="16.22127668418369"/>
<CONT_DATA CI_END="-20.35113735089279" CI_START="-31.0488626491072" EFFECT_SIZE="-25.699999999999996" ESTIMABLE="YES" MEAN_1="-74.3" MEAN_2="-48.6" ORDER="179" SD_1="4.0" SD_2="6.3" SE="2.7290617028161486" STUDY_ID="STD-Connett-1994b" TOTAL_1="9" TOTAL_2="7" WEIGHT="15.985010674806675"/>
<CONT_DATA CI_END="13.320417707538383" CI_START="2.6795822924616175" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="-48.0" MEAN_2="-56.0" ORDER="180" SD_1="9.6" SD_2="8.6" SE="2.7145487108463002" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" WEIGHT="15.99692557902635"/>
<CONT_DATA CI_END="15.516382542689882" CI_START="-89.51638254268988" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="-251.0" MEAN_2="-214.0" ORDER="181" SD_1="100.0" SD_2="100.0" SE="26.79456508228335" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" WEIGHT="2.076391819472017"/>
<CONT_DATA CI_END="-4.214778486038232" CI_START="-10.185221513961775" EFFECT_SIZE="-7.200000000000003" ESTIMABLE="YES" MEAN_1="-65.0" MEAN_2="-57.8" ORDER="182" SD_1="7.5" SD_2="7.5" SE="1.523100188324284" STUDY_ID="STD-Littenberg-1986" TOTAL_1="48" TOTAL_2="49" WEIGHT="16.797068140494424"/>
<CONT_DATA CI_END="4.117007695630561" CI_START="-9.117007695630562" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-57.7" MEAN_2="-55.2" ORDER="183" SD_1="17.3" SD_2="16.1" SE="3.376086370884707" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" WEIGHT="15.411079084956654"/>
<CONT_DATA CI_END="47.52550223234439" CI_START="-35.52550223234439" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-364.0" MEAN_2="-370.0" ORDER="184" SD_1="101.0" SD_2="101.0" SE="21.18687004449686" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" WEIGHT="3.096811445710259"/>
<CONT_DATA CI_END="-2.4574418887507843" CI_START="-19.542558111249214" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-61.0" MEAN_2="-50.0" ORDER="185" SD_1="17.0" SD_2="17.0" SE="4.358528104920205" STUDY_ID="STD-Storr-1987" TOTAL_1="32" TOTAL_2="29" WEIGHT="14.41543657134993"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Adverse effects</NAME>
<DICH_OUTCOME CHI2="2.286464707995723" CI_END="2.3815289087479004" CI_START="0.09577260845541397" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4775827003805329" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="12.528717674668734" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.37685585766515756" LOG_CI_START="-1.0187586840077376" LOG_EFFECT_SIZE="-0.3209514131712901" METHOD="MH" NO="1" P_CHI2="0.31878729595987176" P_Q="0.0" P_Z="0.3673378097062594" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.25861852924447026" TOTALS="YES" TOTAL_1="86" TOTAL_2="82" WEIGHT="100.00000000000001" Z="0.901471275655998">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.831867030809095" CI_START="0.011426127339586065" EFFECT_SIZE="0.29914529914529914" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8938653054196868" LOG_CI_START="-1.9421009402114586" LOG_EFFECT_SIZE="-0.524117817395886" ORDER="186" O_E="0.0" SE="1.665860610943057" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="2.7750915750915746" WEIGHT="22.152977064780416"/>
<DICH_DATA CI_END="1.644155312496379" CI_START="0.015915661902690104" EFFECT_SIZE="0.16176470588235295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2159428400739862" LOG_CI_START="-1.7981752951700085" LOG_EFFECT_SIZE="-0.7911162275480113" ORDER="187" O_E="0.0" SE="1.1831029626878868" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="1.3997326203208555" WEIGHT="40.525621114782865"/>
<DICH_DATA CI_END="23.29217702385835" CI_START="0.17911694281689267" EFFECT_SIZE="2.0425531914893615" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.367210082148365" LOG_CI_START="-0.7468633319406631" LOG_EFFECT_SIZE="0.3101733751038509" ORDER="188" O_E="0.0" SE="1.2418171882680695" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="1.5421099290780143" WEIGHT="37.32140182043673"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6452641474170376" CI_END="1.4752969312185793" CI_START="0.45118928724894375" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8158665153547269" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.16887943903383992" LOG_CI_START="-0.345641220513859" LOG_EFFECT_SIZE="-0.08838089074000952" METHOD="MH" NO="2" P_CHI2="0.9579034155230698" P_Q="0.0" P_Z="0.5007317757131887" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="130" WEIGHT="100.00000000000001" Z="0.6733388040210637">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.499463704230795" CI_START="0.11811686591525188" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.875030207575582" LOG_CI_START="-0.9276880850202806" LOG_EFFECT_SIZE="-0.026328938722349152" ORDER="189" O_E="0.0" SE="1.058925648670276" STUDY_ID="STD-Connett-1994a" TOTAL_1="19" TOTAL_2="18" VAR="1.1213235294117647" WEIGHT="8.146103131811119"/>
<DICH_DATA CI_END="5.3286512701105115" CI_START="0.30398587346666567" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.726617299069512" LOG_CI_START="-0.5171465980294861" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="190" O_E="0.0" SE="0.7305930698865366" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="15" VAR="0.5337662337662338" WEIGHT="17.113141553115078"/>
<DICH_DATA CI_END="2.160530021892624" CI_START="0.18484065336632702" EFFECT_SIZE="0.6319444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3345603054779431" LOG_CI_START="-0.7332025050262552" LOG_EFFECT_SIZE="-0.19932109977415607" ORDER="191" O_E="0.0" SE="0.6272091604013217" STUDY_ID="STD-Lin-1997" TOTAL_1="23" TOTAL_2="22" VAR="0.3933913308913309" WEIGHT="23.21967058607586"/>
<DICH_DATA CI_END="2.3578087237741348" CI_START="0.19529115276849696" EFFECT_SIZE="0.6785714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.37250857023369327" LOG_CI_START="-0.7093174310124738" LOG_EFFECT_SIZE="-0.16840443038939024" ORDER="192" O_E="0.0" SE="0.635469948257071" STUDY_ID="STD-Lin-1999" TOTAL_1="30" TOTAL_2="26" VAR="0.4038220551378446" WEIGHT="22.619906462505227"/>
<DICH_DATA CI_END="2.570863959126129" CI_START="0.28379591687630384" EFFECT_SIZE="0.8541666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.4100790959489648" LOG_CI_START="-0.5469938572606683" LOG_EFFECT_SIZE="-0.06845738065585175" ORDER="193" O_E="0.0" SE="0.5621893903028637" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.3160569105691057" WEIGHT="28.901178266492728"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6324169362094625" CI_END="4.229427227319169" CI_START="0.2561275008791081" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0408038364088184" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.6262815567704079" LOG_CI_START="-0.5915437880336221" LOG_EFFECT_SIZE="0.017368884368392876" METHOD="MH" NO="3" P_CHI2="0.4264703779673069" P_Q="0.0" P_Z="0.955416015980735" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.05590684733067162">
<NAME>Headache</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.268680553788132" CI_START="0.012024137034396348" EFFECT_SIZE="0.3153153153153153" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9174362140354908" LOG_CI_START="-1.9199460829082542" LOG_EFFECT_SIZE="-0.5012549344363818" ORDER="194" O_E="0.0" SE="1.666692406493645" STUDY_ID="STD-Connett-1994b" TOTAL_1="18" TOTAL_2="18" VAR="2.7778635778635774" WEIGHT="18.42189517735877"/>
<DICH_DATA CI_END="6.436535463186557" CI_START="0.28861303554274165" EFFECT_SIZE="1.362962962962963" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8086521664142373" LOG_CI_START="-0.5396840573851767" LOG_EFFECT_SIZE="0.13448405451453033" ORDER="195" O_E="0.0" SE="0.7920193722317265" STUDY_ID="STD-Rodrigo-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.6272946859903381" WEIGHT="81.57810482264124"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Symptoms scores</NAME>
<CONT_OUTCOME CHI2="5.054516076664539" CI_END="0.19949370509928688" CI_START="-0.32282688965287876" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06166659227679594" ESTIMABLE="YES" I2="60.431424696945584" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.07987782132891486" P_Q="1.0" P_Z="0.6435096149332895" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03209224946833971" TOTALS="YES" TOTAL_1="125" TOTAL_2="132" UNITS="" WEIGHT="100.00000000000001" Z="0.46279737435658436">
<NAME>Initial Score</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48677282781396214" CI_START="-0.1667728278139623" EFFECT_SIZE="0.15999999999999992" ESTIMABLE="YES" MEAN_1="-1.95" MEAN_2="-2.11" ORDER="196" SD_1="0.75" SD_2="0.84" SE="0.16672389410800637" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" WEIGHT="29.646286020950907"/>
<CONT_DATA CI_END="0.55524921890691" CI_START="-0.55524921890691" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="-9.2" ORDER="197" SD_1="1.3" SD_2="1.2" SE="0.28329562343320847" STUDY_ID="STD-Tal-1990" TOTAL_1="39" TOTAL_2="39" WEIGHT="15.803389023890471"/>
<CONT_DATA CI_END="-0.15817019249177253" CI_START="-0.24182980750822783" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.0" ORDER="198" SD_1="0.1" SD_2="0.1" SE="0.021342130691265674" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" WEIGHT="54.550324955158636"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.8951424082329487" CI_END="0.056348888378876416" CI_START="-0.5929197657837447" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26828543870243415" ESTIMABLE="YES" I2="74.3269977013843" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="0.04842599116343993" P_Q="1.0" P_Z="0.10528377578007697" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04296100467140005" TOTALS="YES" TOTAL_1="86" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="1.6197603074230522">
<NAME>Final Score</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2671205401772811" CI_START="-0.3871205401772812" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-0.61" ORDER="199" SD_1="0.81" SD_2="0.78" SE="0.16690130163491076" STUDY_ID="STD-Stein-1990" TOTAL_1="44" TOTAL_2="47" WEIGHT="38.739576852225234"/>
<CONT_DATA CI_END="-0.3163403849835446" CI_START="-0.4836596150164552" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.0" ORDER="200" SD_1="0.2" SD_2="0.2" SE="0.04268426138253135" STUDY_ID="STD-Wolfson-1994" TOTAL_1="42" TOTAL_2="46" WEIGHT="61.260423147774766"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-07-23 15:37:21 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-07-23 15:37:21 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any steroid (po, IM, IV, inhaled) vs placebo, outcome: 1.1 Admitted to hospital (all times).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAFACAMAAACRPKR5AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>